

Ramsey M. Al-Salam, Bar No. 109506
RAlsalam@perkinscoie.com
PERKINS COIE LLP
1201 Third Avenue, Suite 4900
Seattle, Washington 98101-3099
Telephone: 206.359.8000
Facsimile: 206.359.9000

Amanda Tessar (admitted *pro hac vice*)
ATessar@perkinscoie.com
PERKINS COIE LLP
1900 Sixteenth Street, Suite 1400
Denver, Colorado 80202-5255
Telephone: 303.291.2300
Facsimile: 303.291.2400

(Additional counsel listed on signature page)

**ATTORNEYS FOR PLAINTIFF
INARI MEDICAL, INC.**

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

INARI MEDICAL, INC.,
Plaintiff,
v.
IMPERATIVE CARE, INC.,
Defendant.

Case No. 5:24-cv-3117-EKL
THIRD AMENDED COMPLAINT FOR
PATENT INFRINGEMENT
DEMAND FOR JURY TRIAL

Inari-2004
Imperative Care, Inc. v. Inari Medical, Inc.
IPR2025-00728

1 1. Plaintiff Inari Medical, Inc. (“Inari”) files this Third Amended Complaint for
2 Patent Infringement against Defendant Imperative Care, Inc. (“Imperative Care,” “Truvic,” or
3 “Defendant”)¹ and respectfully shows the Court as follows:

4 **INTRODUCTION AND SUMMARY OF THE CASE**

5 2. Inari is a pioneering healthcare company with a mission of improving outcomes
6 for patients suffering from life-threatening pulmonary embolism (“PE”) and deep vein
7 thrombosis (“DVT,” blood clots in larger veins, such as in the legs). After years of effort and
8 sustained investment, Inari successfully developed, proved the efficacy of, and received
9 regulatory (FDA) clearance for its transformational (and award-winning) ClotTrieve® and
10 FlowTrieve® systems.

11 3. These thrombectomy devices differ significantly from any prior and competing
12 treatments for PE and DVT. For example, Inari offers a host of product features that are
13 separately and collectively innovative, including but not limited to Inari products’ use of vacuum
14 pressure for aspiration (the “Whoosh”™ technology), their “hemostasis valve” design, their
15 pressure settings, the size of the catheters involved, and their blood filtering and return systems.
16 In recognition of Inari’s contributions, the Patent and Trademark Office has to date awarded
17 Inari dozens of patents.

18 4. This is not to say that it has been a trivial process to educate and win over, one-
19 by-one, the multitude of cardiologists, vascular surgeons, interventional radiologists, and other
20 doctors charged with the treatment of patients suffering from PE and DVT, who are accustomed
21 to the less-effective, traditional treatments for blood clots recommended by the American
22 Medical Association even today. This has taken an extraordinary effort. Through investment,
23 persistence, and superior products, however, Inari has single-handedly created and supplied a
24 market for its aspiration-based mechanical thrombectomy devices, saving patient lives in the
25 process.

27 ¹ Inari’s original complaint named Truvic Medical, Inc. as a defendant. Counsel for Imperative
28 Care has confirmed that Truvic Medical, Inc. was merged out of existence, so this Second
 Amended Complaint removes Truvic Medical, Inc. as a separately named defendant.

of business in this Judicial District.

FACTUAL ALLEGATIONS UNDERLYING INARI'S CLAIMS

Inari's Innovations And Efforts To Develop Its Thrombectomy Products

12. Venous thromboembolism ("VTE") is a disease caused by blood clot formation in the veins of the body, and is, unfortunately, a leading cause of both death and disease worldwide. Pulmonary embolism ("PE") and deep vein thrombosis ("DVT") are common types of VTE. DVT is a type of blood clot that typically forms in the deep veins of a limb, such as the leg, and can develop into PE if portions of the clot break off and migrate to the pulmonary system. PE is a life-threatening condition that occurs when a clot breaks free and becomes lodged in the arteries of the lungs.

13. Inari is the world's leading developer of catheter-based aspiration and/or mechanical thrombectomy devices that treat PE and DVT through aspiration (*e.g.*, by using suction to remove clot material) and/or mechanical mechanisms of action (*e.g.*, using mechanical objects to disrupt clot material). Inari was and is a pioneer in changing the standard of care for PE and DVT from thrombolytics-based treatments (*i.e.*, treatments with drugs called "lytics" that break down blood clots that have formed in blood vessels) and surgeries—which have been plagued with drawbacks relating to effectiveness and side effects—to treatment with aspiration-based mechanical systems. Inari's lifesaving products, including its FlowTrieve and ClotTrieve systems, have received widespread acclaim for their efficacy in treating PE and/or DVT.² Inari's innovations have also been repeatedly recognized by the United State Patent and Trademark Office, which has issued Inari over fifty United States patents and is in the process of allowing additional claims in multiple pending applications.

14. Inari's first product, its FlowTrieve system, represented a major leap in treatment for venous thromboembolism, including PE. During procedures, FlowTrieve targets aspiration (adjustable negative vacuum pressure) directly to the thrombus via catheters. FlowTrieve may be used to facilitate aspiration and removal of the thrombus through, for example, the Trieve24,

² See <https://ir.inarimedical.com/news-events/press-releases>.


1 Trierer20, and/or Trierer16 catheters, aspirating at least a portion of the clot material. The
2 Trierer catheters are introduced through a vascular access sheath into the peripheral vasculature
3 and guided over a guidewire to the site of the thrombus or emboli. The 16F Trierer Catheter
4 and 20F Trierer Catheter are capable of telescoping from the 24F Trierer Catheter for extended
5 reach to the thrombus.³ FlowTrierer generates vacuum using large-bore locking syringes.
6 FlowTrierer's catheter technology further optionally allows for a catheter with expanding mesh
7 disks at the distal end to mechanically engage and disrupt clot materials.

8 15. Inari received FDA clearance for its FlowTrierer system in November 2016. This
9 clearance had indications for use for non-surgical removal of clot material from blood vessels in
10 the peripheral vasculature. This version of FlowTrierer included an Aspiration Guide Catheter,
11 a FlowTrierer Catheter, and a Retraction Aspirator. The FlowTrierer Catheter is inserted
12 through the Aspiration Guide Catheter and advanced to the thrombus (*i.e.*, the blood clot). Self-
13 expanding wireform disks are deployed to engage the thrombus by retracting the outer delivery
14 catheter. The hand-lever operated Retraction Aspirator in this version of FlowTrierer
15 simultaneously aspirates fluids and retracts the FlowTrierer Catheter with at least a portion of
16 the thrombus into the Aspiration Guide Catheter to capture clot and restore blood flow.

17 16. The more recent versions of the FlowTrierer system allow the removal of the
18 FlowTrierer Catheter from the patient and aspiration of clot material through the Aspiration
19 Guide Catheter without the simultaneous removal of the Aspiration Guide Catheter.⁴ A capture
20 from a FlowTrierer video depicting the distal end of a FlowTrierer catheter is below:

21
22
23
24
25
26 ³ The "French" ("F") scale is commonly used to measure the size of catheters. 1 French (1F)
27 equals 1/3 mm.

28 ⁴ See FDA 510(k) Premarket Notification K162970 (available at
https://www.accessdata.fda.gov/cdrh_docs/pdf16/K162970.pdf).



(Guide Catheter (purple), FlowTrievers Catheter (pale blue), and self-expanding wireform disks (grey).)

17. From April 2016 to November 2017, Inari conducted the FlowTrievers Pulmonary Embolectomy Clinical Study (“FLARE”) to evaluate the safety and effectiveness of the FlowTrievers system for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism. The results were strikingly positive.⁵

18. Inari received expanded FDA clearance to market FlowTrievers for treating PE (in addition to the prior clearance for peripheral vasculature generally) in May 2018.⁶ This made FlowTrievers the first FDA-cleared aspiration-mechanical system for treating PE, and the first FDA-cleared aspiration-mechanical system for treating both PE and peripheral vasculature thrombosis. The PE-specific clearance was based upon the strength of the results from the FLARE Clinical Study.⁷

19. Inari continued to improve the performance of FlowTrievers over the years. By December 2018, Inari developed and received FDA clearance for a telescoping version of FlowTrievers, for instance, meaning that a smaller diameter catheter can be advanced through

⁵ See <https://www.clinicaltrials.gov/study/NCT02692586?rank=8&lead=Inari%20Medical>.

⁶ See FDA 510(k) Premarket Notification K180466 (available at https://www.accessdata.fda.gov/cdrh_docs/pdf18/K180466.pdf).

⁷ See <https://ir.inarimedical.com/news-releases/news-release-details/flowtrievers-system-inari-medical-receives-fda-510k-clearance>.

(inside) a larger diameter catheter for extended reach. This version of FlowTrievery includes the Trievery16 Catheter (16F outer catheter), the Trievery20 Catheter (20F outer catheter), the FlowTrievery Catheter, and two Large Bore 60cc Syringes, one for Trievery16 and one for Trievery20, for aspiration purposes. The Trievery16 Catheter is capable of extending through and past the distal end from the Trievery20 Catheter to reach the thrombus. Each Trievery Catheter is connected to a pressure source, such as a Large Bore 60cc Syringe.

20. From December 2018 to February 2019, Inari conducted a limited market release of the telescoping FlowTrievery and gathered physician feedback according to a clinical evaluation plan. The positive evaluation results proved the telescoping combination of Trievery16 and Trievery20 to be excellent for treating large RV (right ventricular)/LV (left ventricular) clots in the left pulmonary arteries, vasculature with challenging anatomy, and the distal segments with occlusive clot. Overall, using the telescoping combination is more efficient than using a single outer catheter.

21. By September 2019, Inari developed and received FDA clearance for Trievery24, a 24F outer catheter.⁸ This catheter can be used in a telescoping combination with Trievery16.

22. Separately from its work on FlowTrievery, Inari also received FDA clearance for its ClotTrievery system in February 2017. ClotTrievery was designed for clot removal, including for acute and chronic clots (i.e., including DVT) using mesh forms to engage and then withdraw clots.⁹


23. The first version of ClotTrievery consists of the ClotTrievery Sheath and the ClotTrievery Catheter. The ClotTrievery Sheath consists of a polymeric sheath equipped with a self-expanding distal mesh funnel, a flush/aspiration port with tubing clamp, and a proximal hemostatic valve. The ClotTrievery Catheter consists of three preassembled polymeric coaxial catheters terminating in an expandable member and tissue collection net. At the proximal end

⁸ See FDA 510(k) Premarket Notification K191710 (available at https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191710.pdf).

⁹ See FDA 510(k) Premarket Notification K193462 (available at https://www.accessdata.fda.gov/cdrh_docs/pdf19/K193462.pdf).

of the catheter is a handle used to enable expansion of the expandable member and net.

24. The expanded structures of the ClotTrievers are drawn through the vessel obstruction to capture clot and restore blood flow by “non-surgical removal of soft thrombi and emboli from blood vessels.”¹⁰ A figure depicting the ClotTrievers system is shown below:



25. As with FlowTrievers, Inari continues to improve the performance of ClotTrievers over the years. By December 2017, Inari had developed and received FDA clearance for replacing the tissue collection net with a collapsible clot collection bag.¹¹ In September 2018, Inari started the ClotTrievers Outcomes (“CLOUT”) Registry Clinical Study to evaluate real-world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity DVT with the ClotTrievers system. Inari announced the interim results of the study on March 12, 2024, with the results showing that ClotTrievers significantly reduced rates of “post-thrombotic syndrome” over historical DVT trials.¹² On September 9, 2020, Inari received FDA clearance

¹⁰ See FDA 510(k) Premarket Notification K163549 (available at https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163549.pdf).

¹¹ See FDA 510(k) Premarket Notification K173470 (available at https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173470.pdf).

¹² See <https://ir.inarimedical.com/node/10506/pdf>.

1 to market ClotTrievers specifically for the treatment of DVT.¹³

2 **Truvic's Copycat Devices**

3 26. Founded in 2016, Imperative Care is a medical technology company developing
4 products in a wide array of disparate health-related areas. For instance, its various products
5 include ones directed at stroke solutions, vascular disease treatments, digital health, and robotics.

6 27. In July 2021, Imperative Care acquired Truvic Medical, Inc.,¹⁴ a thrombectomy
7 device developer that, based on recorded filings, was incorporated in 2020. Truvic Medical, Inc.
8 has two lines of thrombectomy products—the Prodigy Thrombectomy System (“Prodigy”) and
9 the Symphony Thrombectomy System (“Symphony” or “Symphony system”). Symphony is the
10 system that most directly competes with Inari’s treatment systems, while Prodigy targets clots in
11 much smaller arteries.

12 28. Like FlowTrievers and ClotTrievers, Symphony is intended for the non-surgical
13 removal of fresh, soft emboli and thrombi from blood vessels. The Symphony system as a whole
14 is comprised of at least the 24F Symphony Catheter, 16F Symphony Catheter (with a working
15 length of either 82 cm or 117 cm), Truvic Generator, 24F Symphony Dilator, 16F Symphony
16 Dilator, Truvic Canister, 24F Symphony Advance Long Dilator, 16F Symphony ProHelix,
17 Truvic Tubeset, and 24F Symphony ProHelix, although not all parts of the system need to be or
18 are used for every patient procedure, and Truvic may have or be developing additional
19 components for or to be used with the Symphony system. The Symphony system, like Inari’s
20 products, is designed to remove thrombus/embolus from veins and large arteries using controlled
21 aspiration. The Symphony Catheter targets aspiration from the Truvic Generator directly to the
22 thrombus. The Symphony ProHelix may be used to facilitate aspiration and removal of the
23 thrombus through the Symphony Catheter by mechanically engaging and disrupting the clot
24 material. The Symphony Catheters and Symphony Dilators are introduced through a vascular
25

26 ¹³ See FDA 510(k) Premarket Notification K193462 (available at
27 https://www.accessdata.fda.gov/cdrh_docs/pdf19/K193462.pdf).

28 ¹⁴ All references to “Truvic” should be understood to include Imperative Care, unless the context dictates otherwise.

1 access sheath into the peripheral vasculature and guided over a guidewire to the site of the
2 thrombus. The Symphony Catheter is used with the Truvic Generator, connected using the
3 Truvic Tubeset and the Truvic Canister, to aspirate thrombus. The 16F Symphony Catheter is
4 capable of telescoping from the 24F Symphony Catheter for, *inter alia*, extended reach to the
5 thrombus. As needed, the Symphony ProHelix may be introduced through the Symphony
6 Catheter to assist with thrombus removal. The Symphony ProHelix is manually advanced
7 through the Symphony Catheter over a guidewire, remaining inside the Symphony Catheter
8 during the procedure. During aspiration, the handle on the proximal end of the Symphony
9 ProHelix is manually rotated, which rotates the tip of the Symphony ProHelix to facilitate
10 thrombus removal through the Symphony Catheter.¹⁵

11 29. In February 2023, Truvic received FDA clearance to market its Symphony
12 system.¹⁶ This FDA clearance is limited to marketing Symphony for DVT treatment. It is
13 common in the industry for doctors to use cleared FDA devices to treat problems beyond those
14 for which they are indicated, however—a phenomenon often referred to as “off-label” usage.
15 For instance, now that Truvic can sell its Symphony systems for DVT, doctors might also use
16 those systems for the treatment of PE. In fact, there have been scattered reports that doctors are
17 already doing exactly that with Truvic’s systems at least occasionally, including with procedures
18 where Truvic sales representatives have participated.

19 30. Truvic began marketing and selling its Symphony system to physicians and
20 hospitals by no later than mid-2023, after it had received its FDA clearance for DVT.

21 31. In an October 2023 submission to ClinicalTrials.gov, Imperative Care stated that
22 it will conduct a clinical study to evaluate the safety and efficacy of Symphony in the treatment
23

24
25 ¹⁵ Inari has obtained information regarding the design and operation of the Symphony system
26 from multiple sources, including Truvic’s product brochure (attached as Exhibit A), its FDA-
27 cleared “Instructions for Use” (“IFU”) (attached as Exhibit B), a video on Symphony’s
28 website (available at <https://www.truvic.com/symphony-product> and at
<https://vimeo.com/817718796>), and its own examinations of a Symphony system.

¹⁶ See 510(k) Premarket Notification K223216 (available at
https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223216.pdf).

1 of PE from December 2023 to April 2025.¹⁷ Upon completion of this study, the FDA will
2 presumably clear TruVic to market Symphony for the treatment of PE. At that point, Inari
3 expects that Symphony usage for PE will increase from a trickle of off-label uses by particular
4 doctors to a much larger flow of regular PE procedures. Upon information and belief, TruVic
5 began marketing and selling its Symphony system to physicians and hospitals that engaged in
6 procedures for PE in approximately mid-2023, after TruVic had received its FDA clearance for
7 DVT.

8 32. TruVic designed its Symphony system after Inari had introduced FlowTrieve into
9 the market. TruVic's Symphony system significantly overlaps with and mirrors the FlowTrieve
10 design. The two products share many similar features and mechanisms, such as telescoping
11 aspiration catheters (including 16F catheters inserted through a 24F catheter), an intervening
12 member used in addition to the catheter, the design of a hemostasis valve between the aspiration
13 catheter and the aspiration source, and the design of the removable clot-filtering canister.

14 33. There is a long list of other indicia that TruVic has intentionally copied Inari's
15 devices and is doing its best to target the market that Inari has created from scratch. For instance,
16 TruVic has been systematically recruiting and attempting (sometimes successfully) to hire away
17 key Inari personnel, including sales representatives, apparently intent on drawing on their
18 product knowledge and the network of connections they created through Inari's investments.
19 Additionally, TruVic has been systematically targeting the network of doctors who have become
20 top Inari customers for TruVic's own sales, which allows TruVic to save the time and cost of
21 converting doctors from traditional treatments like lytics. Instead, TruVic is simply stealing
22 market share created by Inari's efforts that have begun to shift the VTE treatment paradigm.
23 TruVic sales representatives have also persuaded doctors to allow them to observe procedures
24 performed with Inari devices, which is highly unusual, and—even more unusually—have
25 sometimes convinced doctors to exclude Inari sales representatives from being present when
26 procedures are performed with Inari's own devices.

27 ¹⁷ See [https://www.clinicaltrials.gov/study/NCT06062329?rank=1&lead=Imperative%](https://www.clinicaltrials.gov/study/NCT06062329?rank=1&lead=Imperative%20Care,%20Inc)
28 [20Care,%20Inc.](https://www.clinicaltrials.gov/study/NCT06062329?rank=1&lead=Imperative%20Care,%20Inc)

34. Inari contacted TruViv in September 2023, just months after TruViv had obtained FDA clearance for Symphony, to give notice of Inari’s patents. In response, TruViv refused to provide Inari with one of its Symphony systems for analysis, claiming that the Symphony systems—*i.e.*, the same systems already being used by doctors in patient procedures—is “confidential.” TruViv’s response was irregular and concerning.

35. Upon information and belief, Truvic has been producing, using, promoting, selling, and inducing physicians and hospitals to buy and use the Symphony system. For example, Truvic's sales representatives have successfully convinced and are successfully convincing physicians, such as those at Beaumont Health and Cardiovascular Institute of the South (to name just a few hospitals), to perform thrombectomy procedures with Symphony, displacing sales and/or sales opportunities for Inari products.

36. Based upon the promotional literature that Truvic has distributed and made available online, as well as statements and actions by Truvic's sales representatives and Inari's own examination of a Symphony system that Inari very recently obtained, Truvic directly and indirectly infringes the Inari patents described below through manufacture, sale, offer for sale, and/or use of the Symphony products.

The Patents-In-Suit

37. On May 7, 2024, the United States Patent and Trademark Office duly and legally issued United States Patent No. 11,974,910 (“the ’910 Patent”), entitled “System for Treating Embolism and Associate Devices and Methods.” Inari owns all rights, title, and interest in and to the ’910 Patent and possesses all rights of recovery under the ’910 Patent. A true and correct copy of the ’910 Patent is attached as Exhibit C.

38. The '910 Patent is valid and enforceable.

39. On April 30, 2024, the United States Patent and Trademark Office duly and legally issued United States Patent No. 11,969,333 (“the 11-’333 Patent”), entitled “System for Treating Embolism and Associate Devices and Methods.” Inari owns all rights, title, and interest in and to the 11-’333 Patent and possesses all rights of recovery under the 11-’333 Patent. A true and correct copy of the 11-’333 Patent is attached as Exhibit D.

1 40. The 11-'333 Patent is valid and enforceable.

2 41. On January 17, 2023, the United States Patent and Trademark Office duly and
3 legally issued United States Patent No. 11,554,005 ("the '005 Patent"), entitled "System for
4 Treating Embolism and Associated Devices and Methods." Inari owns all rights, title, and
5 interest in and to the '005 Patent and possesses all rights of recovery under the '005 Patent. A
6 true and accurate copy of the '005 Patent is attached as Exhibit E.¹⁸

7 42. The '005 Patent is valid and enforceable.

8 43. On September 5, 2023, the United States Patent and Trademark Office duly and
9 legally issued United States Patent No. 11,744,691 ("the '691 Patent"), entitled "System for
10 Treating Embolism and Associated Devices and Methods." Inari owns all rights, title, and
11 interest in and to the '691 Patent and possesses all rights of recovery under the '691 Patent. A
12 true and accurate copy of the '691 Patent is attached as Exhibit F.¹⁹

13 44. The '691 Patent is valid and enforceable.

14 45. On December 19, 2023, the United States Patent and Trademark Office duly and
15 legally issued United States Patent No. 11,844,921 ("the '921 Patent"), entitled "Hemostasis
16 Valves and Methods of Use." Inari owns all rights, title, and interest in and to the '921 Patent
17 and possesses all rights of recovery under the '921 Patent. A true and accurate copy of the '921
18 Patent is attached as Exhibit G.

19 46. The '921 Patent is valid and enforceable.

20 47. On July 11, 2023, the United States Patent and Trademark Office duly and legally
21 issued United States Patent No. 11,697,012 ("the '012 Patent"), entitled "Hemostasis Valves and
22 Methods of Use." Inari owns all rights, title, and interest in and to the '012 Patent and possesses
23 all rights of recovery under the '012 Patent. A true and accurate copy of the '012 Patent is
24 attached as Exhibit H.

26 ¹⁸ Inari recently filed a revised certificate of correction to add two inadvertently omitted
27 inventors, John Thress and Paul Lubock, to the '005 Patent.

28 ¹⁹ Inari recently filed a revised certificate of correction to add two inadvertently omitted
inventors, John Thress and Paul Lubock, to the '691 Patent.

1 48. The '012 Patent is valid and enforceable.

2 49. On January 9, 2024, the United States Patent and Trademark Office duly and
3 legally issued United States Patent No. 11,865,291 (“the '291 Patent”), entitled “Hemostasis
4 Valves and Methods of Use.” Inari owns all rights, title, and interest in and to the '291 Patent
5 and possesses all rights of recovery under the '291 Patent. A true and accurate copy of the '291
6 Patent is attached as Exhibit I.

7 50. The '291 Patent is valid and enforceable.

8 51. On June 25, 2024, the United States Patent and Trademark Office duly and legally
9 issued United States Patent No. 12,016,580 (“the '580 Patent”), entitled “Single Insertion
10 Delivery System for Treating Embolism and Associated Systems and Methods.” Inari owns all
11 rights, title, and interest in and to the '580 Patent and possesses all rights of recovery under the
12 '580 Patent. A true and accurate copy of the '580 Patent is attached as Exhibit J.

13 52. The '580 Patent is valid and enforceable.

14 53. On October 8, 2024, the United States Patent and Trademark Office duly and
15 legally issued United States Patent No. 12,109,384 (“the '384 Patent”), entitled “Hemostasis
16 Valves and Methods of Use.” Inari owns all rights, title, and interest in and to the '384 Patent
17 and possesses all rights of recovery under the '384 Patent. A true and accurate copy of the '384
18 Patent is attached as Exhibit K.

19 54. The '384 Patent is valid and enforceable.

20 55. On December 3, 2024, the United States Patent and Trademark Office duly and
21 legally issued United States Patent No. 12,156,669 (“the '669 Patent”), entitled “Single Insertion
22 Delivery System for Treating Embolism and Associated Systems and Methods.” Inari owns all
23 rights, title, and interest in and to the '669 Patent and possesses all rights of recovery under the
24 '669 Patent. A true and accurate copy of the '669 Patent is attached as Exhibit L.

25 56. The '669 Patent is valid and enforceable.

26 57. On March 4, 2025, the United States Patent and Trademark Office duly and legally
27 issued United States Patent No. 12,239,333 (“the 12-'333 Patent”), entitled “Single Insertion
28 Delivery System for Treating Embolism and Associated Systems and Methods.” Inari owns all

1 rights, title, and interest in and to the 12-'333 Patent and possesses all rights of recovery under
2 the 12-'333 Patent. A true and accurate copy of the 12-'333 Patent is attached as Exhibit W.

3 58. The 12-'333 Patent is valid and enforceable.

4 **Inari Put Truvic On Notice Of Its Infringement, But Truvic Refused To Stop**

5 59. In September 2023, after Truvic had received FDA clearance to market its
6 Symphony system and Inari began to hear reports that Truvic was beginning to do so, Inari wrote
7 to Defendant to inform them of Inari's belief that Defendant was infringing at least United States
8 Patent Nos. 11,559,382 and 11,744,691 and that Defendant would infringe other allowed claims
9 of pending applications in the "System for Treating Embolism and Associate Devices and
10 Methods" family and the pending claims of Published Application No. 17/498,642 (which has
11 since issued as the '580 Patent) once those claims issued. Inari further explained that it believed
12 that the hemostasis valves in the Symphony system might infringe Inari's hemostasis valve
13 patents, including: United States Patent Nos. 11,554,005, 11,697,012, and allowed claims of
14 Application No. 18/142,518 (later issued as United States Patent No. 11,865,291). The letter
15 further attached the ten patents and applications referenced. Inari's letter requested that Truvic
16 provide a sample Symphony product for analysis (*e.g.*, including to confirm its hemostasis valve
17 design) and requested that Defendant cease or delay its launch of its Symphony products until
18 patent issues were resolved. Inari also invited a dialogue and asked Defendant to identify any
19 genuine basis that they had for believing that they were not infringing Inari's patents.

20 60. On December 1, 2023, Truvic replied by email, refusing to provide a sample
21 Symphony product because "details of the Symphony product are proprietary, and at this time
22 we are not willing to provide a sample to you that would allow you to benefit from the
23 product...."

24 61. On January 15, 2024, almost four months after Inari's letter, Truvic finally
25 provided a substantive response to Inari's September 2023 letter. For all but one of the patents
26 that Inari had identified, Truvic did not identify a single noninfringement argument. Instead,
27 Truvic argued that the patents were invalid based on identified prior art.

28 62. On April 24, 2024, Inari sent another letter to Truvic, responding to Truvic's

1 invalidity allegations and identifying multiple additional Inari patents that Truvic is infringing.
2 For instance, Inari explained that it had received notices of allowance for the patent applications
3 that have now issued as the '910 and 11-'333 Patents (and that are asserted here). Inari explained
4 that the claims in these new patents were issuing over the prior art identified by Truvic and that
5 the Symphony system would practice these patents upon issuance. The letter further explained
6 that Inari had been able to analyze a Symphony system and had now concluded that the
7 hemostasis valves of the Symphony system indeed infringe the '005, '921, '012, and '291
8 Patents, as had been suggested was likely in Inari's September 2023 letter.

9 63. On February 14, 2025, Inari sent an e-mail to counsel for Truvic that the 12-'333
10 Patent would be issuing on March 4, 2025 and that Inari intended to assert infringement and
11 serve supplemental contentions and amend its complaint, adding the 12-'333 Patent.

12 64. Despite Inari's notice to Defendant by a series of letters and emails, Defendant has
13 continued to market infringing Symphony systems. Inari is therefore forced to file this suit.

14 **COUNT 1: INFRINGEMENT OF THE '910 PATENT**

15 65. Inari realleges and incorporates by reference the preceding paragraphs as though
16 fully set forth herein.

17 66. The '910 Patent is titled "System for Treating Embolism and Associated Devices
18 and Methods." The '910 Patent discloses improved clot-removing systems and methods for
19 pulmonary embolisms that solve problems with prior art clot-removal devices. The '910 Patent
20 solves these problems through its inventions that include, for example, an aspiration system
21 configured to allow for aspiration using vacuum, comprising both a first and second aspiration
22 system comprising, respectively: a first and second catheter; a first and second pressure source;
23 and a first and second fluid control device between the respective catheters and pressure sources.
24 (Ex. C at cl. 1.) Each of the fluid control devices can be moved between a first position where
25 the pressure source is disconnected from the catheter (allowing the pressure source to generate
26 vacuum pressure) and a second position where the pressure source is fluidly connected to the
27 catheter (where vacuum from the pressure source generates suction at the distal end of the
28 catheter). (*See id.*) The '910 Patent teaches that the second aspiration catheter of the second

1 aspiration assembly is advanceable through the first aspiration catheter of the first aspiration
 2 assembly and that the second catheter has a size of 16F, while the first catheter has a size of 24F.
 3 (*See id.* at cl. 1, cl. 3.)

4 67. Defendant directly infringes—literally and/or under the doctrine of equivalents—
 5 at least claims 1 and 3 of the '910 Patent by making, using, selling, offering for sale, and/or
 6 importing into the United States its Symphony system and components thereof.

7 68. The Symphony system practices each limitation of at least claims 1 and 3 of the
 8 '910 Patent.

9 69. For example, claim 1 of the '910 Patent recites:

10 [1] A clot treatment system for treating clot material comprising a pulmonary
 11 embolism in a vasculature of a patient, comprising:

12 a first clot aspiration assembly, including:

13 a first catheter;

14 a first pressure source; and

15 a first fluid control device between the first catheter and the first pressure source,
 16 wherein the first fluid control device is movable between (a) a first position in
 17 which the first pressure source is fluidly disconnected from the first catheter and
 18 (b) a second position in which the first pressure source is fluidly connected to the
 19 first catheter,

20 wherein the first pressure source is configured to generate vacuum pressure while
 21 the first fluid control device is in the first position, and wherein, upon movement
 22 of the first fluid control device from the first position to the second position, the
 23 vacuum pressure is applied to the first catheter to generate suction at a distal
 24 portion of the first catheter; and

25 a second clot aspiration assembly, including:

26 a second catheter advanceable through the first catheter, wherein the second
 27 catheter has a distal portion, wherein the second catheter has a size of 16 French
 28 or greater, and wherein the second catheter is shaped to be intravascularly
 advanced through the vasculature of the patient such that the distal portion of the
 second catheter is positioned proximate to the pulmonary embolism;

a second pressure source; and

a second fluid control device between the second catheter and the second pressure
 source,

wherein the second fluid control device is movable between (a) a first position in
 which the second pressure source is fluidly disconnected from the second catheter
 and (b) a second position in which the second pressure source is fluidly connected


1 to the second catheter,

2 wherein the second pressure source is configured to generate vacuum pressure
3 while the second fluid control device is in the first position, and wherein, upon
4 movement of the second fluid control device from the first position to the second
5 position, the vacuum pressure is applied to the second catheter to generate suction
at the distal portion of the second catheter to aspirate blood and at least a portion
of the pulmonary embolism into the second catheter.

6 70. Claim 3 further recites: “[t]he clot treatment system of claim 1 wherein the first
7 catheter has a size of 24 French, and wherein the size of the [] second catheter [] is 16 French.”

8 71. To the extent the preamble of claim 1 is construed to be limiting, the TruVie
9 Symphony system practices the requirements of the preamble, “[a] clot treatment system for
10 treating clot material comprising a pulmonary embolism in a vasculature of a patient,” as can be
11 seen in the claim chart in Exhibit M. Specifically, the Symphony system is a clot treatment
12 system for treating clot material from pulmonary embolisms, “[t]he TruVie Symphony
13 Thrombectomy System employs “next generation thrombus removal” with “powerful, focused
14 aspiration” for treating (*e.g.*, removing) clot material from within a blood vessel.” (Ex. A at 2-
15 4.) The Symphony system is further a system for treating clot material comprising a pulmonary
16 embolism in the vasculature of the patient, as demonstrated by: doctors’ use of the system for
17 exactly that purpose; the Symphony system being used in clinical trials for treatment of
18 pulmonary embolisms; and Defendant seeking clearance for using the Symphony system for
19 treatment of pulmonary embolism (clot material in the pulmonary vasculature). *See*
20 SYMPHONY-PE Study for Treatment of Pulmonary Embolism (available at
21 <https://classic.clinicaltrials.gov/ct2/show/NCT06062329>).

22 72. The Symphony system practices the limitations of claim 1, including “a first clot
23 aspiration assembly, including: a first catheter; a first pressure source; and a first fluid control
24 device between the first catheter and the first pressure source,” as can be seen in claim chart in
25 Exhibit M. The Symphony system includes a 24F catheter (first catheter), a vacuum pump and
26 a clot canister comprising the first pressure source, and a controller handle for a 24F catheter
27 including a Dual-Action Vacuum Control operated by a lever (a first fluid control device)
28 between the 24F catheter and the first pressure source:



(Ex. A at 2 (annotations added).)




(Annotated diagram of Symphony system handle, including the first catheter, connection to a first pressure source (clot canister and vacuum pump), and a first fluid control device (the Dual-Action Vacuum Control operated by a lever).)


73. The Symphony system practices the limitations of claim 1, including “wherein the first fluid control device is movable between (a) a first position in which the first pressure source is fluidly disconnected from the first catheter and (b) a second position in which the first pressure

source is fluidly connected to the first catheter,” as can be seen in claim chart in Exhibit M. The Symphony system includes a Dual-Action Vacuum Control operated by a lever (a first fluid control device) between the 24F catheter and the first pressure source (comprised of the clot canister and the vacuum pump) that in a first position (off) fluidly disconnects the first pressure source from the 24F catheter and that in a second position (on) fluidly connects the first pressure source to the 24F catheter:

First fluid control device in “On” position such that the first pressure source is fluidly connected to the 24F catheter such that the clot material is aspirated into the clot canister




(Annotated screen capture from Symphony product video.)



13 (Annotated image of internal portion of controller handle housing.)



25 (Annotated image of Symphony housing (internal).)



(Annotated screen capture from Symphony product video.)



(Annotated image of Symphony housing (internal).)

1 74. The Symphony system practices the limitations of claim 1, including “wherein the
2 first pressure source is configured to generate vacuum pressure while the first fluid control device
3 is in the first position, and wherein, upon movement of the first fluid control device from the
4 first position to the second position, the vacuum pressure is applied to the first catheter to
5 generate suction at a distal portion of the first catheter,” as can be seen in claim chart in Exhibit
6 M. The Symphony system includes a controller handle for a 24F catheter including a Dual-
7 Action Vacuum Control operated by a lever (a first fluid control device) between the 24F catheter
8 and the first pressure source (comprised of the clot canister and the vacuum pump) that in a first
9 position (off) fluidly disconnects the first pressure source from the 24F catheter and that in a
10 second position (on) fluidly connects the first pressure source to the 24F catheter. As detailed
11 above, the first pressure source (clot canister and vacuum pump) creates a vacuum in the clot
12 canister while the handle lever is in the first (off) position, and then vacuum pressure is applied
13 to the first (24F) catheter to generate suction at the distal portion of the catheter (positioned near
14 the clot material) when the handle lever is moved from the first position to the second (on)
15 position:
16
17
18
19
20
21
22
23
24
25
26
27
28

13. Confirm that both the 24F and 16F Handle vacuum levers are in the "OFF" position.




Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister

14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the "ON" position.


(Ex. B at 8.)

75. The Symphony system practices the limitations of claim 1, including "a second clot aspiration assembly, including: a second catheter advanceable through the first catheter, wherein the second catheter has a distal portion, wherein the second catheter has a size of 16 French or greater, and wherein the second catheter is shaped to be intravascularly advanced through the vasculature of the patient such that the distal portion of the second catheter is positioned proximate to the pulmonary embolism," as can be seen in claim chart in Exhibit M.

1 Specifically, the Symphony system has a second aspiration assembly including a second (16F)
2 catheter that can be advanced through the first (24F) catheter, where the second (16F) catheter
3 is shaped to be telescoped through the 24F catheter and advanced through a patient's vasculature
4 to position the distal end of the second catheter proximate to clot material, *e.g.*, a pulmonary
5 embolism:




(Screen capture from Symphony product video.)




(Ex. A at 4 (annotations added).)

76. The Symphony system practices the limitations of claim 1, including “a second pressure source; and a second fluid control device between the second catheter and the second pressure source, wherein the second fluid control device is movable between (a) a first position in which the second pressure source is fluidly disconnected from the second catheter and (b) a second position in which the second pressure source is fluidly connected to the second catheter,” as can be seen in claim chart in Exhibit M. The Symphony system includes a 16F catheter (second catheter), a vacuum pump and a clot canister comprising the second pressure source, and a controller handle for a 16F catheter including a Dual-Action Vacuum Control operated by a lever (a second fluid control device) between the 16F catheter and the second pressure source:




(Ex. A at 2 (annotations added).)




(Annotated diagram of Symphony system handle, including the second catheter, connection to a second pressure source (clot canister and vacuum pump), and a second fluid control device (the Dual-Action Vacuum Control operated by a lever).)


77. The vacuum control lever of the second fluid control device can be moved from the first (off) position where the second catheter is fluidly disconnected from the second pressure source to a second (on) position where the second catheter is fluidly connected to the second pressure source:




(Annotated screen capture from Symphony product video.)



(Annotated image of internal portion of controller handle housing.)



(Annotated image of Symphony housing (internal).)



(Annotated screen capture from Symphony product video.)



(Annotated image of Symphony housing (internal).)

78. The Symphony system practices the limitations of claim 1, including “wherein the second pressure source is configured to generate vacuum pressure while the second fluid control device is in the first position, and wherein, upon movement of the second fluid control device from the first position to the second position, the vacuum pressure is applied to the second catheter to generate suction at the distal portion of the second catheter to aspirate blood and at least a portion of the pulmonary embolism into the second catheter,” as can be seen in claim chart in Exhibit M. The Symphony system includes a controller handle for a 16F catheter including a Dual-Action Vacuum Control operated by a lever (a second fluid control device) between the 16F catheter and the second pressure source (comprised of the clot canister and the vacuum pump) that in a first position (off) fluidly disconnects the second pressure source from the 16F catheter and that in a second position (on) fluidly connects the second pressure source to the 16F catheter. As detailed above, the second pressure source (clot canister and vacuum pump) creates a vacuum in the clot canister while the handle lever is in the first (off) position, and then vacuum pressure is applied to the second (16F) catheter to generate suction at the distal portion of the catheter (positioned near the clot material) when the handle lever is moved from the first position to the second (on) position:

13. Confirm that both the 24F and 16F Handle vacuum levers are in the “OFF” position.




Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister

14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the “ON” position.

(Ex. B at 8.)

79. Additionally, the Symphony system practices claim 3 of the '910 Patent, which recites “[t]he clot treatment system of claim 1 wherein the first catheter has a size of 24 French, and wherein the size of the [] second catheter [] is 16 French,” as can be seen in the attached Exhibit M. As can be seen above, the Symphony system includes a 24F catheter that is advanced into a patient’s vasculature during thrombectomy procedures, including a 16F catheter telescoped through the 24F catheter.

80. Defendant directly infringes claims of the '910 Patent, including claims 1 and 3, by making, using, selling, offering for sale, and/or importing Symphony system products and their components, and when persons under Defendant’s direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures on pulmonary embolisms) Symphony system products.

1 81. Defendant induces infringement of claims of the '910 Patent, including claims 1
2 and 3, by selling Symphony systems (and components thereof) and teaching or directing others,
3 including physicians, to use Symphony systems that practice claims 1 and 3. Defendant actively
4 induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures on patients with
5 pulmonary embolisms.

6 82. On information and belief, Defendant teaches and/or direct others to perform
7 thrombectomy on pulmonary embolisms using the Symphony system (and components thereof),
8 despite not having received an indication for use for treatment of pulmonary embolisms.
9 Defendant, for example, provides Instructions for Use that state that "Symphony Thrombectomy
10 System is designed to remove thrombus/embolus (hereupon referred to as 'thrombus' or 'clot')
11 from the vasculature using controlled aspiration." (Ex. B at 2.) Defendant further provides
12 brochures and other materials, including animations videos, that detail how to use the TruVie
13 Symphony system. (See, *e.g.*, <https://www.truvic.com/symphony-product>.) Upon information
14 and belief, Defendant's sales representatives additionally attend procedures and instruct
15 physicians regarding methods of using the TruVie Symphony system, including on information
16 and belief, methods of treating pulmonary embolisms. Defendant additionally is in the process
17 of seeking FDA clearance for the treatment of PE and have an announced intention to formally
18 market its Symphony system to do so.

19 83. Defendant further engages in contributory infringement by offering to sell, selling,
20 and/or importing into the United States the Symphony system (and components thereof),
21 knowing that these are apparatuses for use in a patented process and constitute a material part of
22 the invention that is especially made or adapted for infringement of the claims of the '910 Patent
23 and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

24 84. Defendant's infringement is with knowledge of the '910 Patent and its claims.
25 Specifically, as described above, Inari notified Defendant, by letter dated April 24, 2024, that
26 the claims of United States Patent Application No. 18/329,433 ("the '433 Application") were
27 scheduled to issue shortly as the '910 Patent and further provided notice that claims 1 and 3 of
28 the '433 Application read on the Symphony system and that Defendants would be infringing the

1 '910 Patent upon its issuance. Inari further attached the notice of allowance for the '433
2 Application that became the '910 Patent.

3 85. At a minimum, Defendant has notice of the '910 Patent through the filing of the
4 original Complaint, which was submitted to the Court just a few weeks after the '910 Patent
5 issued.

6 86. Defendant has continued its infringing activities after the '910 Patent issued,
7 despite knowledge of the allowed claims (including knowledge from correspondence with Inari
8 and through the original Complaint), and such infringement has been and continues to be
9 egregious and willful.

10 87. To the extent applicable, the requirements of 35 U.S.C. § 287(a) have been met
11 for the '910 Patent, including through the use of Inari's virtual marking website:
12 <https://www.inarimedical.com/inari-patents>.

13 88. To the extent applicable, the requirements of 35 U.S.C. § 154(d) have been met
14 for the allowed claims of the '433 Application from April 24, 2024, to the issuance of the '910
15 Patent.

16 89. Defendant's infringement has caused and will continue to cause Inari substantial
17 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

18 **COUNT 2: INFRINGEMENT OF THE 11-'333 PATENT**

19 90. Inari realleges and incorporates by reference the preceding paragraphs as though
20 fully set forth herein.

21 91. Defendant directly and indirectly infringes—literally and/or under the doctrine of
22 equivalents—at least claims 20 and 22 of the 11-'333 Patent by making, using, selling, offering
23 for sale, and/or importing into the United States its Symphony system and components thereof.

24 92. The 11-'333 Patent, titled "System for Treating Embolism and Associated Devices
25 and Methods," is part of the same family as the '910 Patent, and shares the same specification.
26 Similar to the '910 Patent, the 11-'333 Patent discloses improved methods of treatment for
27 removing clot material (*e.g.*, thrombi and emboli) from blood vessels of a human patient,
28 particularly from deep veins (DVT or deep vein thromboses) or pulmonary vasculature

(pulmonary embolisms) of human patient. (Ex. D at 4:51-58.) This is accomplished by aspirating the clot material through a catheter fluidly coupled to a pressure source via a valve. (*Id.* at 4:17-25.) The 11-'333 Patent explains that prior art clot-removal devices have been found: to be highly complex and lead to manufacturing and quality control difficulties, as well as delivery issues into patients; to cause trauma to the treatment vessel; to lack the ability to be appropriately fixed against the vessel; and/or to be ineffective at capturing clot material. (*Id.* at 2:33-44.) The 11-'333 Patent solves these problems through its inventions, which include, for example, methods comprising advancing a catheter within a patient's vasculature to treat pulmonary embolism or deep vein thrombosis. (*Id.* at cl. 1, cl. 20.) The aspiration catheter has its distal end placed proximate to the clot material (pulmonary embolism or deep vein thrombosis), while the aspiration catheter lumen is fluidly connected along a path to a clot canister and to an aspiration source proximal to the clot canister. (*Id.*) The methods further comprise steps of generating vacuum pressure in the path between the clot canister and aspiration catheter while a valve is in a first position that inhibits fluid flow from the aspiration catheter to the clot canister, and then moving the valve to a second position that permits fluid flow along the path from the lumen of the aspiration catheter to the clot canister, thereby applying vacuum pressure to the lumen of the aspiration catheter and aspirating at least a portion of clot material into the clot canister. (*Id.*) The 11-'333 Patent further claims aspects of aspiration systems, including a clot canister with a filter-to-filter blood from clot material (*id.*), performing the method with large (16F or 20F or larger diameter catheters (*id.* at cl. 2, cl. 3 cl. 21, cl. 22), and performing the method on clot material in the pulmonary artery (*id.* at cl. 4) or peripheral vasculature of the patient (*id.* at cl. 24).

93. Specifically, claim 20 of the 11-'333 Patent recites:

[20] A method of treating a deep vein thrombosis within a vasculature of a patient, the method comprising:

advancing an aspiration catheter at least partially through the vasculature of the patient such that a distal end portion of the aspiration catheter is positioned proximate to the deep vein thrombosis, wherein a lumen of the aspiration catheter is fluidly coupled along a fluid path to a clot canister and an aspiration source proximal to the clot canister;

generating vacuum pressure within the clot canister via the aspiration source while a valve positioned along the fluid path between the aspiration catheter and the clot canister is in a first position that inhibits fluid flow along the fluid path from the lumen of the aspiration catheter to the clot canister; and

moving the valve from the first position to a second position thereby applying the vacuum pressure to the lumen of the aspiration catheter such that at least a portion of the deep vein thrombosis and blood are aspirated into the clot canister, wherein in the second position the valve permits fluid flow along the fluid path from the lumen of the aspiration catheter to the clot canister,

and wherein the clot canister includes a filter configured to filter the blood from the portion of the deep vein thrombosis.


94. Claim 22 of the 11-'333 Patent further recites: “[t]he method of claim 20 wherein advancing the aspiration catheter comprises inserting a catheter having a size of 20 French or greater through the vasculature.”

95. Performing thrombectomy on deep vein thrombosis using the TruVic Symphony system practices each limitation of at least claims 20 and 22 of the 11-'333 Patent, as can be seen in the 11-'333 Patent claim chart, attached as Exhibit N.


96. To the extent the preamble of claim 20 is construed to be limiting, thrombectomy of deep vein thrombosis with the Symphony system practices the requirements of the preamble, “[a] method of treating a deep vein thrombosis within a vasculature of a patient, the method comprising,” as can be seen in Exhibit N. For example, according to TruVic’s Symphony Brochure, Symphony employs “next generation thrombus removal” with “powerful, focused aspiration” for treating (*e.g.*, removing) clot material from within a blood vessel. (*See* Ex. A at 2-4.) Symphony’s “Instructions for Use” further instruct that the system “is indicated for: [t]he non-surgical removal of fresh, soft emboli and thrombi from blood vessels.” (Ex. B at 12.) In addition, Symphony’s product website includes a video detailing a method of using Symphony to treat clot material within a blood vessel of a human patient using vacuum aspiration. *See* <https://www.truvic.com/symphony-product>.

97. Thrombectomy with the Symphony system practices the limitations of claim 20, including “advancing an aspiration catheter at least partially through the vasculature of the patient such that a distal end portion of the aspiration catheter is positioned proximate to the deep


1 vein thrombosis,” as can be seen in Exhibit N. The Symphony system includes a 24F catheter
2 (a “first catheter”) and a 16F catheter (a “second catheter”). (*Id.* at 2, 4.) These catheters can be
3 used as aspiration catheters, and the TruVic Symphony system is “intended for use in the
4 peripheral vasculature,” such as for deep vein thrombosis.



14 (Ex. A at 2 (annotations added).)




26 (Annotated screen capture from Symphony product video.)



(Ex. A at 4 (annotations added).)

98. In thrombectomy operation, the 16F second catheter can be advanced, including through the 24F first catheter and out of the 24F first catheter, through the vasculature of a patient over a guidewire and/or with a dilator positioned therein (as shown in the image below) until a distal portion of the 16F second catheter is positioned just proximal of clot material within a blood vessel of the vasculature. (See *id.* at 4.) The 24F catheter can also be advanced to a position proximal to the clot material within a blood vessel of the patient's vasculature.




(Ex. A at 4 (annotations added).)




(Annotated screen capture from Symphony product video.)

99. Thrombectomy with the Symphony system practices the limitations of claim 20, including “wherein a lumen of the aspiration catheter is fluidly coupled along a fluid path to a

clot canister and an aspiration source proximal to the clot canister,” as can be seen in Exhibit N. Specifically, in the Symphony system, the 24F and 16F catheters have lumens that are coupled along a fluid path in the controller handle, and then to an aspiration source that includes a vacuum pump that is located proximal to the clot canister. This can further be seen in the annotated diagrams below:




(Annotated diagram of Symphony system.)



(Annotated diagram of the Symphony system.)



(Annotated diagram of Symphony housing with flow path.)



(Annotated image of internal portion of controller handle housing with flow path.)

100. Thrombectomy with the Symphony system practices the limitations of claim 20, including “generating vacuum pressure within the clot canister via the aspiration source while a valve positioned along the fluid path between the aspiration catheter and the clot canister is in a first position that inhibits fluid flow along the fluid path from the lumen of the aspiration catheter to the clot canister” and “moving the valve from the first position to a second position thereby applying the vacuum pressure to the lumen of the aspiration catheter such that at least a portion of the deep vein thrombosis and blood are aspirated into the clot canister, wherein in the second position the valve permits fluid flow along the fluid path from the lumen of the aspiration catheter to the clot canister,” as can be seen in Exhibit N. In the Symphony system, the 24F and 16F

controller handles are coupled to a Truvic Generator and Truvic Canister, or another pressure source, which is a vacuum pressure source:

13. Confirm that both the 24F and 16F Handle vacuum levers are in the "OFF" position.





Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister


14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the "ON" position.

(Ex. B at 8.)

101. During thrombectomy using the Symphony system, the user initially sets the vacuum control lever on the 16F and/or 24F handles to the "OFF" position, which actuates a vacuum valve in the handle, ensuring that vacuum is not applied to the lumen of the 16F and/or 24F aspiration catheters:




(Annotated diagram of Symphony system.)



(Annotated image of Symphony housing (internal).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


Vacuum control valve in OFF position



(Annotated image of Symphony housing (internal).)

Vacuum control lever in "Off" position such that the clot canister is fluidly disconnected from the 16F catheter such that aspiration is not applied to the clot material

To vacuum pump aspiration source




(Annotated screen capture from Symphony product video.)


102. During thrombectomy using the Symphony system, the user moves the vacuum lever on the 16F and/or 24F handles to the "ON" position, which actuates a valve in the handle,

applying vacuum to the lumen of the 16F and/or 24F aspiration catheters:


Vacuum control lever in "On" position such that the clot canister is fluidly connected to the 24F catheter such that the clot material (deep vein thrombosis) is aspirated into the clot canister



(Annotated screen capture from Symphony product video.)





15 (Annotated image of Symphony housing (internal).)



27 (Annotated image of internal portion of controller handle housing.)


103. Thrombectomy with the Symphony system practices the limitations of claim 20, including “wherein the clot canister includes a filter configured to filter the blood from the portion of the deep vein thrombosis,” as can be seen in Exhibit N. Specifically, the clot canisters of the 24F and 16F handles have a filter that filters the blood from the aspirated portion of the clot material, such as a deep vein thrombosis. This allows the blood to pass through the canister, while the clot canister traps the clot material of a deep vein thrombosis.





(Annotated screen captures from Symphony product video.)

104. Additionally, thrombectomy with the Symphony system practices claim 22 of the 11-'333 Patent, which recites “[t]he method of claim 20 wherein advancing the aspiration catheter comprises inserting a catheter having a size of 20 French or greater through the vasculature,” as can be seen in the attached Exhibit N. The Symphony system includes a 24F catheter that is advanced into a patient’s vasculature during thrombectomy procedures, including for deep vein thrombosis, as recited in claim 20 and analyzed above.



(Annotated screen capture from Symphony product video.)

1 105. Defendant directly infringes claims of the 11-'333 Patent, including claims 20 and
2 22, when Defendant or persons under its direction and control perform thrombectomy procedures
3 on deep vein thromboses. For example, Defendant directly infringes claims 20 and 22 when
4 testing or using the Symphony system in patients.

5 106. Defendant induces infringement of claims of the 11-'333 Patent, including claims
6 20 and 22, by selling Symphony systems (and components thereof) and teaching or directing
7 others, including physicians, to use the Symphony systems in a manner that practices the
8 methods of claims 20 and 22. Defendant actively induces users of the system, *e.g.*, doctors, to
9 perform thrombectomy procedures on deep vein thromboses with the Truvic Symphony system
10 in a manner that practices the limitations of claims of the 11-'333 Patent, including claims 20
11 and 22. Defendant instructs and teaches users to perform methods that practice the limitations
12 of claims 20 and 22 with knowledge and/or willful blindness that such acts constitute direct
13 infringement of the 11-'333 Patent.

14 107. Defendant, for example, provides Instructions for Use that state that the
15 “Symphony Thrombectomy System is intended for: The non-surgical removal of fresh, soft
16 emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is intended
17 for use in the peripheral vasculature.” (Ex. B at 2.) The IFU further states that the “Symphony
18 Thrombectomy System is designed to remove thrombus/embolus (hereupon referred to as
19 ‘thrombus’ or ‘clot’) from the vasculature using controlled aspiration.” (*Id.* at 1.) Defendant
20 further provides brochures and other materials, including animations videos, that detail how to
21 use the Truvic Symphony system in a manner that practices claims of the 11-'333 Patent,
22 including claims 20 and 22. (See, *e.g.*, <https://www.truvic.com/symphony-product>.) Upon
23 information and belief, Defendant’s sales representatives additionally attend procedures and
24 instruct physicians regarding methods of using the Truvic Symphony system, including methods
25 of treating deep vein thrombosis that practice the 11-'333 Patent.

26 108. Defendant further engages in contributory infringement by offering to sell, selling,
27 and/or importing into the United States the Symphony system (and components thereof),
28 knowing that these are apparatuses for use in a patented process and constitute a material part of

1 the invention that is especially made or adapted for infringement of the claims of the 11-'333
2 Patent and not a staple article or commodity of commerce suitable for substantial non-infringing
3 uses.

4 109. Defendant's infringement is with knowledge of the 11-'333 Patent and its claims.
5 Specifically, as described above, Inari notified Defendant, by letter dated April 24, 2024, that
6 the claims of United States Patent Application No. 18/329,450 ("the '450 Application") were
7 scheduled to issue shortly as the 11-'333 Patent and further provided notice that claims 42 and
8 44 of the '450 Application (renumbered as claims 20 and 22 of the 11-'333 Patent) read on the
9 Symphony system and that Defendant would be infringing the 11-'333 Patent upon its issuance.
10 Inari further attached the notice of allowance and the issue notification for the 11-'333 Patent.

11 110. At a minimum, Defendant has notice of the 11-'333 Patent through the filing of
12 the original Complaint, which was submitted to the Court just a few weeks after the 11-'333
13 Patent issued.

14 111. Defendant has continued its infringing activities after the 11-'333 Patent issued,
15 despite knowledge of the 11-'333 Patent (including knowledge from correspondence with Inari
16 and from the original Complaint), and such infringement has been and continues to be egregious
17 and willful.

18 112. The requirements of 35 U.S.C. § 287(a) have been met for the 11-'333 Patent.
19 Because the 11-'333 Patent contains only method claims, no marking is required.

20 113. To the extent applicable, the requirements of 35 U.S.C. § 154(d) have been met
21 for the allowed claims of the '450 Application from April 24, 2024, to the issuance of the 11-
22 '333 Patent.

23 114. Defendant's infringement has caused and will continue to cause Inari substantial
24 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

25 **COUNT 3: INFRINGEMENT OF THE '005 PATENT**

26 115. Inari realleges and incorporates by reference the preceding paragraphs as though
27 fully set forth herein.

28 116. The '005 Patent, titled "System for Treating Embolism and Associated Devices

and Methods,” is part of the same family as the ’910 and 11-’333 Patents, and shares the same specification. Similar to the ’910 and 11-’333 Patents, the ’005 Patent discloses improved clot-removing systems and methods that solve problems with prior art clot-removal devices. The ’005 Patent solves these problems through its inventions that include, for example, a vacuum aspiration system comprising a flow path extending through a housing with an on-off control in the flow path, a catheter, and a clot canister fluidly coupled to the flow path, where the housing further includes an improved hemostasis valve that is configured to receive a second catheter and direct it through the first catheter. (Ex. E at cl. 1.)

117. Defendant directly infringes—literally and/or under the doctrine of equivalents—at least claim 10 of the ’005 Patent by making, using, selling, offering for sale, and/or importing into the United States its Symphony system and components thereof.

118. The Symphony system practices each limitation of at least claim 10 of the ’005 Patent.

119. For example, claim 10 of the ’005 Patent recites:

[10] A vacuum aspiration system, comprising:

a housing;

a flow path extending through the housing;

an on-off control in the flow path;

a first catheter in fluid communication with the flow path and a connector configured to place a source of aspiration in communication with the flow path;

a clot cannister fluidly coupled to the flow path; and

a hemostasis valve in the housing configured to receive a second catheter and direct the second catheter through the first catheter, wherein the hemostasis valve comprises:

(a) a support;

(b) an actuator having a least a first member movably coupled to the support;

(c) a collapsible tubular sidewall defining a lumen carried by the support;

(d) a filament formed in a loop around the tubular sidewall, the filament having at least a first end portion extending away from the loop to the first member; and

(e) a first spring configured to move the first member in a direction that pulls

the first end portion such that a diameter of the lumen decreases in response to reducing a diameter of the loop.

120. To the extent the preamble of claim 10 is construed to be limiting, the TruVie Symphony system practices the preamble, a “vacuum aspiration system, comprising,” as can be seen in the claim chart in Exhibit O. Specifically, the Symphony system is a vacuum aspiration system for treating clots: “The Symphony Thrombectomy System is designed to remove thrombus/embolus ... from the vasculature using controlled aspiration.” (Ex. B at 1.)

121. The Symphony system practices the limitations of claim 10, including “a housing; a flow path extending through the housing; an on-off control in the flow path; a first catheter in fluid communication with the flow path and a connector configured to place a source of aspiration in communication with the flow path; a clot cannister fluidly coupled to the flow path,” as can be seen in the claim chart in Exhibit O. The Symphony system includes controller handles (a housing), one for each of a 24F and 16F catheter:






Figure 3: Symphony Catheter Handle, labeled

(Ex. B at 4.)



(Ex. A at 2 (annotations added).)

122. The Symphony handle (housing) includes a flow path through the handle extending from the catheter (in fluid communication with the flow path) through the housing, the on-off control valve, the clot canister, the tubing (connector) to the vacuum pump (source of aspiration) that fluidly connects the lumen of the 24F aspiration catheter (first catheter), the on-off control valve, the clot canister, the tubing (connector), and the vacuum pump (source of aspiration):




(Annotated diagram of Symphony housing with flow path.)

123. The Symphony system practices the limitations of claim 1, including “a hemostasis valve in the housing configured to receive a second catheter and direct the second

1 catheter through the first catheter, wherein the hemostasis valve comprises” as can be seen in
2 claim chart in Exhibit O. The Symphony system includes a controller handle with a hemostasis
3 valve in the controller housing:

4 5 High-Powered, Continuous 6 Vacuum with Real-Time 7 Case Assessment

8 BigShot™ Controller




21 (Ex. A at 6.)
22
23
24
25
26
27
28



(Image of internal portion of housing with hemostasis valve.)

124. The Symphony system practices the limitations of claim 1, including “(a) a support; (b) an actuator having a least a first member movably coupled to the support; (c) a collapsible tubular sidewall defining a lumen carried by the support; (d) a filament formed in a loop around the tubular sidewall, the filament having at least a first end portion extending away from the loop to the first member; (e) a first spring configured to move the first member in a direction that pulls the first end portion such that a diameter of the lumen decreases in response to reducing a diameter of the loop,” as can be seen in claim chart in Exhibit O. The hemostasis valve in each of the Symphony handles includes a plastic support. It also includes an actuator mechanism having a first member including a first button that pushes against a first lever and second member including a second button that pushes against a second lever, where the lever and buttons are biased outwardly by a first torsion spring(s) and a second torsion spring(s), and the valve has a lumen carried by a plastic support and that can be constricted by first and second filament lines looped around the lumen and wrapped around pins in the first lever and the second lever. This structure can be seen in the annotated picture of the Symphony system below:



(Annotated image of internal portion of Symphony housing, including hemostasis valve.)

125. The torsion springs drive the lever outward such that the pins of the levers tension the filament lines wrapped around the pins of the levers and wrapped in a loop around the tubular member (lumen) of the hemostasis valve to constrict the collapsible sidewall of the lumen by reducing the diameter of the filament loops around it.

126. Defendant directly infringes claims of the '005 Patent, including claim 10, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant's direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures) Symphony system products.

127. Defendant induces infringement of claims of the '005 Patent, including claim 10, by selling Symphony systems (and components thereof) and teaching or directing others, including physicians, to use the Symphony systems that practice claims 10. Defendant actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using the Symphony system.

1 128. Defendant teaches and/or directs others to perform thrombectomy on, for example,
2 deep vein thrombosis using the Symphony system (and components thereof). Defendant, for
3 example, provides Instructions for Use that state that the “Symphony Thrombectomy System is
4 intended for: The non-surgical removal of fresh, soft emboli and thrombi from blood vessels....
5 The Symphony Thrombectomy System is intended for use in the peripheral vasculature.” (Ex.
6 B at 2.) The IFU further states that the “Symphony Thrombectomy System is designed to remove
7 thrombus/embolus (hereupon referred to as ‘thrombus’ or ‘clot’) from the vasculature using
8 controlled aspiration.” (*Id.* at 1.) Defendant further provides brochures and other materials,
9 including animations videos, that detail how to use the TruVie Symphony system. (*See, e.g.,*
10 <https://www.truvic.com/symphony-product>.) Upon information and belief, Defendant’s sales
11 representatives additionally attend procedures and instruct physicians regarding methods of
12 using the TruVie Symphony system, including on information and belief, methods of treating
13 thrombi and emboli.

14 129. Defendant further engages in contributory infringement by offering to sell, selling,
15 and/or importing into the United States the Symphony system (and components thereof),
16 knowing that these are apparatuses for use in a patented process and constitute a material part of
17 the invention that is especially made or adapted for infringement of the claims of the ’005 Patent
18 and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

19 130. Defendant’s infringement is with knowledge of the ’005 Patent and its claims.
20 Specifically, as described above, Inari notified Defendant, by letter dated September 29, 2023,
21 that the Symphony system might infringe the ’005 Patent. Inari further explained, by letter dated
22 April 24, 2024, that a teardown of the hemostasis valves in the Symphony system showed that
23 they infringe Inari’s patents.

24 131. At a minimum, Defendant has notice of the ’005 Patent through the filing of the
25 original Complaint.

26 132. Defendant has continued its infringing activities, despite knowledge of the ’005
27 Patent (including knowledge from correspondence with Inari and through the original
28 Complaint), and such infringement has been and continues to be egregious and willful.

1 133. To the extent applicable, the requirements of 35 U.S.C. § 287(a) have been met
2 for the '005 Patent, including through the use of Inari's virtual marking website:
3 <https://www.inarimedical.com/inari-patents>.

4 134. Defendant's infringement has caused and will continue to cause Inari substantial
5 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

6 **COUNT 4: INFRINGEMENT OF THE '691 PATENT**

7 135. Inari realleges and incorporates by reference the preceding paragraphs as though
8 fully set forth herein.

9 136. The '691 Patent, titled "System for Treating Embolism and Associated Devices
10 and Methods," is part of the same family as the '910, 11-'333, and '005 Patents, and it shares the
11 same specification. Similar to the '910, 11-'333, and '005 Patents, the '691 Patent discloses
12 improved clot-removing systems and methods that solve problems with prior art clot-removal
13 devices. The '691 Patent solves these problems through its inventions that include, for example,
14 an aspiration system with accelerated response, comprising an aspiration pump coupled with a
15 first chamber, an aspiration catheter in fluid communication in communication with the first
16 chamber via an aspiration tube, further having a second chamber between the aspiration pump
17 and the second chamber that is removable, and where the system has a user-actuable valve
18 between the second chamber and the aspiration catheter to connect or disconnect negative
19 pressure, allowing pressure to build up in the first and second chambers before connecting
20 negative pressure to the aspiration catheter to aspirate clot material. (*See* Ex. F at cl. 14.)
21 Dependent claims further recite that the system is for treating deep vein thrombosis. (*Id.* at cl.
22 22.)

23 137. Defendant directly infringes—literally and/or under the doctrine of equivalents—
24 at least claims 14 and 22 of the '691 Patent by making, using, selling, offering for sale, and/or
25 importing into the United States its Symphony system and components thereof.

26 138. The Symphony system practices each limitation of at least claims 14, 19, 20, and
27 22 of the '691 Patent.
28

139. For example, claim 14 of the '691 Patent recites:

[14] An aspiration system with accelerated response, comprising:

an aspiration pump in communication with a first chamber;

an aspiration catheter configured for placement into fluid communication with the first chamber by way of an aspiration tube;

a second chamber in between the aspiration pump and the aspiration catheter, wherein the second chamber is removably coupled between the aspiration pump and the aspiration catheter; and

a user-actuatable valve between the second chamber and the aspiration catheter, wherein the valve is configured to be closed while negative pressure is generated in the first and second chambers, and wherein the valve is configured to be opened after the negative pressure is generated in the first and second chambers;

wherein upon user actuation to open the valve with negative pressure having been generated in the first and second chambers, fluid flow at least partially from the second chamber into the first chamber causes rapid decrease in pressure in the aspiration catheter.

140. Claim 19 of the '691 Patent depends from claim 14 and further recites "[t]he aspiration system of claim 14 wherein the aspiration catheter is configured to be intravascularly positioned within a blood vessel of a patient."

141. Claim 20 of the '691 Patent depends from claim 19 and further recites "[t]he aspiration system of claim 19 wherein the aspiration catheter has a distal end portion configured to be positioned proximate to clot material within the blood vessel of the patient."

142. Claim 22 of the '691 Patent depends from claim 20 and further recites "[t]he aspiration system of claim 20 wherein the clot material comprises a deep vein thrombus."

143. To the extent the preamble of claim 14 is construed to be limiting, the TruViv Symphony system practices the requirements of the preamble, "[a]n aspiration system with accelerated response, comprising," as can be seen in the claim chart in Exhibit P. Specifically, the Symphony system is a vacuum aspiration system with accelerated response used for treating clots: "[t]he TruViv Symphony Thrombectomy System employs "next generation thrombus removal" with "powerful, focused aspiration" for treating (*e.g.*, removing) clot material from within a blood vessel." (Ex. A at 2-4.).

144. The Symphony system practices the limitations of claim 14, including “an aspiration pump in communication with a first chamber,” as can be seen in claim chart in Exhibit P. The Symphony system includes the Truvic Generator comprising a vacuum pump (aspiration pump), an aspiration tube, and a first vacuum chamber (the Truvic Canister):



(Annotated image of Truvic Generator.)

13. Confirm that both the 24F and 16F Handle vacuum levers are in the “OFF” position.





Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister


14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the “ON” position.

(Ex. B at 8.)


145. The Symphony system practices the limitations of claim 1, including “an aspiration catheter configured for placement into fluid communication with the first chamber by way of an aspiration tube,” as can be seen in claim chart in Exhibit P. The Symphony system includes 24F and 16F catheters in fluid communication with the first chamber of the Truvic Generator through a controller handle by way of an aspiration tube:




(Ex. A at 6 (annotations added).)



(Ex. A at 7 (annotations added).)




(Ex. A at 2 (annotations added).)




(Annotated diagram of Symphony housing with flow path.)

146. The Symphony system practices the limitations of claim 14, including “a second chamber in between the aspiration pump and the aspiration catheter, wherein the second chamber is removably coupled between the aspiration pump and the aspiration catheter,” as can be seen in claim chart in Exhibit P. The Symphony system includes a second chamber on both the 24F and 16F handle controllers, as both have a clot canister that is a second chamber between the aspiration pump (TruVic Generator) and the aspiration catheter, with the clot canister being removable to clean the aspirated clot material filtered from blood:



(Annotated screen capture from Symphony product video.)




(Ex. A at 6 (annotations added).)




(Annotated screen captures from Symphony product video.)

147. The Symphony system practices the limitations of claim 14, including “a user-actuable valve between the second chamber and the aspiration catheter, wherein the valve is configured to be closed while negative pressure is generated in the first and second chambers, and wherein the valve is configured to be opened after the negative pressure is generated in the

first and second chambers,” as can be seen in claim chart in Exhibit P. The Symphony system includes a both the 24F and 16F handle controllers each having a user-actuable valve in the controller that is controlled by the vacuum control lever on the handles, where negative pressure is generated in the Truvic Canister and the clot container by the Truvic Generator while the vacuum control lever valve is closed (“off”), and negative pressure is applied to the aspiration catheter when the valve is opened (“on”):




(Annotated diagram of Symphony system.)




(Annotated image of internal portion of controller handle housing.)



(Annotated image of Symphony housing (internal).)



(Annotated screen capture from Symphony product video.)



(Annotated image of Symphony housing (internal).)

24
25
26
27
28

148. The TruViv Symphony system Instructions For Use further teaches the process of building vacuum of at least -20 inHg using the TruViv Generator when the valve is in the closed (off) position and then moving the control letter to the open (on) position to apply negative pressure to the aspiration catheter:

13. Confirm that both the 24F and 16F Handle vacuum levers are in the "OFF" position.





Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister

14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the "ON" position.


(Ex. B at 8.)

149. The Symphony system practices the limitations of claim 14, including "wherein upon user actuation to open the valve with negative pressure having been generated in the first and second chambers, fluid flow at least partially from the second chamber into the first chamber causes rapid decrease in pressure in the aspiration catheter," as can be seen in claim chart in Exhibit P. As discussed above, when the user actuates the vacuum control lever on the 24F or 16F handle of the Symphony system, the negative (vacuum) pressure generated in the first and second chambers is applied to the aspiration catheter, the fluid flow from the aspiration catheter to the first and second chambers causes a rapid decrease in the pressure in the aspiration catheter to aspirate clot material.

1 150. The Symphony system practices the limitations of claim 22, including claims 14,
2 19, and 20 (from which it depends), including “[t]he aspiration system of claim 14 wherein the
3 aspiration catheter is configured to be intravascularly positioned within a blood vessel of a
4 patient” and “[t]he aspiration system of claim 19 wherein the aspiration catheter has a distal end
5 portion configured to be positioned proximate to clot material within the blood vessel of the
6 patient,” as can be seen in claim chart in Exhibit P. The Symphony system includes 24F and
7 16F catheters that are configured to be positioned within a blood vessel with a distal end of the
8 catheter positioned proximate to clot material within the blood vessel:



21 (Annotated screen capture from Symphony product video.)
22
23
24
25
26
27
28



(Ex. A at 4 (annotations added).)

151. The Symphony system practices the limitations of claim 22, including claims 14, 19, and 20 (from which it depends), including “[t]he aspiration system of claim 20 wherein the clot material comprises a deep vein thrombus,” as can be seen in claim chart in Exhibit P. As discussed above with respect to claim 20 of the ’691 Patent, the Symphony system is a treatment system used for fresh soft emboli in the peripheral vasculature of a patient, *e.g.*, for treating DVT.

152. Defendant directly infringes claims of the ’691 Patent, including claims 14 and 22, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant’s direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures) Symphony system products.

153. Defendant induces infringement of claims of the ’691 Patent, including claims 14 and 22, by selling Symphony systems (and components thereof) and teaching or directing others,

1 including physicians, to use the Symphony systems that practice claims 14 and 22. Defendant
2 actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using
3 the Symphony system.

4 154. Defendant teaches and/or directs others to perform thrombectomy on, for example,
5 deep vein thrombosis using the Symphony system (and components thereof). Defendant, for
6 example, provides Instructions for Use that state that the “Symphony Thrombectomy System is
7 intended for: The non-surgical removal of fresh, soft emboli and thrombi from blood vessels....
8 The Symphony Thrombectomy System is intended for use in the peripheral vasculature.” (Ex.
9 B at 2.) The IFU further states that the “Symphony Thrombectomy System is designed to remove
10 thrombus/embolus (hereupon referred to as ‘thrombus’ or ‘clot’) from the vasculature using
11 controlled aspiration.” (*Id.* at 1.) Defendant further provides brochures and other materials,
12 including animations videos, that detail how to use the TruVic Symphony system. (*See, e.g.*,
13 <https://www.truvic.com/symphony-product>.) Upon information and belief, Defendant’s sales
14 representatives additionally attend procedures and instruct physicians regarding methods of
15 using the TruVic Symphony system, including on information and belief, methods of treating
16 thrombi and emboli.

17 155. Defendant further engages in contributory infringement by offering to sell, selling,
18 and/or importing into the United States the Symphony system (and components thereof),
19 knowing that these are apparatuses for use in a patented process and constitute a material part of
20 the invention that is especially made or adapted for infringement of the claims of the ’691 Patent
21 and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

22 156. Defendant’s infringement is with knowledge of the ’691 Patent and its claims.
23 Specifically, as described above, Inari notified Defendant, by letter dated September 29, 2023,
24 that the Symphony system infringes the ’691 Patent. Inari further explained to Defendant, by
25 letter dated April 24, 2024, that the Symphony system infringes various claims of the ’691 Patent,
26 including claim 22 directed to deep vein thrombosis (DVT) treatment systems.

27 157. At a minimum, Defendant has notice of the ’691 Patent through the filing of the
28 original Complaint, which was submitted to the Court just a few weeks after the ’691 Patent

1 issued.

2 158. Defendant has continued its infringing activities, despite knowledge of the '691
3 Patent (including knowledge from correspondence with Inari and through the original
4 Complaint), and such infringement has been and continues to be egregious and willful.

5 159. Defendant's infringement has caused and will continue to cause Inari substantial
6 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

7 **COUNT 5: INFRINGEMENT OF THE '921 PATENT**

8 160. Inari realleges and incorporates by reference the preceding paragraphs as though
9 fully set forth herein.

10 161. The '921 Patent, titled "Hemostasis Valves and Methods of Use," discloses
11 improved hemostasis valves and methods of their use. (*See, e.g.*, Ex. G at Abstract, 1:58-62.)
12 Hemostasis valves are used to seal, *e.g.*, to seal around catheters, in order to minimize blood loss,
13 and maintain sterility within the body, such as in a blood vessel. (*Id.* at 1:28-44.) This is critical
14 during surgical procedures to prevent patients from losing blood unnecessarily, to prevent air
15 from entering into the vasculature (which can cause bubbles), and to reduce infection. (*See id.*
16 at 1:18-26.) Improved hemostasis valves are important to maximize patient outcomes, including
17 by providing ease of use (*e.g.*, one-handed use) for doctors and practitioners and effective
18 sealing. (*See id.* at 1:45-54, 5:49-67.)

19 162. The '921 Patent discloses hemostasis valves having an internal elongate member
20 with a lumen (an inner cavity through which something can be inserted), which can be
21 constricted and sealed by a filament wrapped at least partially around, *e.g.*, in a loop around, the
22 tube defining a lumen, where the hemostasis valve further has an actuator (such as a button
23 control mechanism) biased to constrict the elongate member's lumen with the filament and that
24 can be moved between a first position where the lumen is constricted (closing the valve) and to
25 a second position where the lumen is not as constricted (at least partially opening the valve).
26 (*See id.* at cl. 1, Fig. 7, 2:8-25.) Some embodiments disclosed by the '921 Patent have multiple
27 actuators and/or two or more filaments looping at least partially around the elongate member.
28 (*See id.* at cl. 1, cl. 10.)

1 163. Defendant directly and indirectly infringes—literally and/or under the doctrine of
2 equivalents—at least claims 1 and 10 of the '921 Patent by making, using, selling, offering for
3 sale, and/or importing into the United States its Symphony system and components thereof.

4 164. The hemostasis valve in the controller handles (housings) of the Symphony system
5 practice each limitation of at least claims 1 and 10 of the '921 Patent.

6 165. For example, claim 1 of the '921 Patent recites:

7 [1] A valve, comprising:

8 an elongate member defining a lumen;

9 an active tensioning mechanism including an actuator coupled to the elongate
10 member via a filament extending at least partially around the elongate member,
11 wherein the actuator is moveable between (a) a first position wherein the lumen is
12 constricted and sealed and (b) a second position wherein the lumen is at least
13 partially open; and

14 a biasing member configured to bias the actuator to the first position.

15 166. Claim 10 of the '921 Patent further recites:

16 [10] The valve of claim 1 wherein the actuator is a first actuator, wherein the
17 filament is a first filament, wherein the biasing member is a first biasing member,
18 and wherein the active tensioning mechanism further comprises:

19 a second actuator coupled to the elongate member via a second filament extending
20 at least partially around the elongate member, wherein the second actuator is
21 moveable between (a) a first position wherein the lumen is constricted and sealed
22 and (b) a second position wherein the lumen is at least partially open; and
23 a second biasing member configured to bias the second actuator to the first
24 position.


25 167. The hemostasis valves of the Symphony system practice the requirements of claim
26 1, including the preamble, “[a] valve, comprising,” as can be seen in Exhibit Q. Specifically, the
27 controller handles of the Symphony system include a hemostasis valve operated by blue buttons
28 (in the 24F handle) and orange buttons (in the 16F handle). The documentation for the
Symphony system makes clear that the controller handles have a hemostasis valve, controlled by
the buttons on the handles, as can be seen in the excerpts and the teardown photos below.




(Ex. A at 2.)

High-Powered, Continuous Vacuum with Real-Time Case Assessment

BigShot™ Controller



(Annotated Ex. A at 6.)



15 (Image of internal portion of housing with hemostasis valve.)




28 (Image of internal portion of housing zoomed in on hemostasis valve.)


1 168. The hemostasis valves of the Symphony system practice the requirements of claim
2 1, including “an elongate member defining a lumen,” as can be seen in Exhibit Q. Specifically,
3 the controller handles of the Symphony system include a hemostasis valve operated by blue
4 buttons (in the 24F handle) and orange buttons (in the 16F handle) that include an elongate
5 member that defines a lumen.



6
7
8
9
10
11
12
13
14
15
16
17 (Image of internal portion of housing with hemostasis valve.)
18
19
20
21
22
23
24
25
26
27
28




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)




(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve open.)

169. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “an active tensioning mechanism including an actuator coupled to the elongate member via a filament extending at least partially around the elongate member, wherein the actuator is moveable between (a) a first position wherein the lumen is constricted and sealed and (b) a second position wherein the lumen is at least partially open,” as can be seen in Exhibit Q. Specifically, the controller handles of the Symphony system include a hemostasis valve with an active tensioning mechanism where a first and second button control first and second levers and first and second pins coupled to lines (filaments) that loop around the valve’s elongate tubular member defining a lumen. The first button/lever/pin to which the first end of the filament line is coupled moves between a first (undepressed button) position where the lumen of the valve is constricted to a second (depressed button) position wherein the lumen is less constricted and at least partially open.




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)


1 170. In operation, depressing the hemostasis valve button(s) of the Symphony system
2 controller handles pushes the lever(s) against the torsion spring(s), releasing tension on the
3 filaments wrapped around the lever pin(s), which decreases the constriction on the lumen of the
4 hemostasis valve. This allows the valve to at least partially open, permitting the introduction of
5 a catheter or other tool through the hemostasis valve. Releasing the button(s), causes the torsion
6 spring(s) to drive the lever outward, increasing tension on the filament lines, sealing the
7 hemostasis valve.



8
9
10
11
12
13
14
15
16
17
18
19
20
21 (Symphony handle with view down elongate member (lumen) of hemostasis valve with
22 valve constricted.)
23
24
25
26
27
28




(Internal image of hemostasis valve with filaments encircling and constricting elongate member.)




(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve open.)

171. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “a biasing member configured to bias the actuator to the first position.” as can be

seen in Exhibit Q. The hemostasis valves of the Symphony handles include a first torsion spring(s) that pushes against the first lever, biasing the actuator to a first position (closed/constricted with an undepressed first button). There are two torsion springs for each of the first lever and the second lever.




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)




(Annotated X-ray imaging of housing showing annotated first and second buttons, first and second levers, and first torsion springs and second torsion springs.)

1 172. The hemostasis valves of the Symphony system practice the requirements of claim
2 10, including “[t]he valve of claim 1 wherein the actuator is a first actuator, wherein the filament
3 is a first filament, wherein the biasing member is a first biasing member, and wherein the active
4 tensioning mechanism further comprises:” as can be seen in Exhibit Q. The hemostasis valves
5 of the Symphony system comprise a first actuator, as alleged above for claim 1.

6 173. The hemostasis valves of the Symphony system practice the requirements of claim
7 10, including “a second actuator coupled to the elongate member via a second filament extending
8 at least partially around the elongate member, wherein the second actuator is moveable between
9 (a) a first position wherein the lumen is constricted and sealed and (b) a second position wherein
10 the lumen is at least partially open,” as can be seen in Exhibit Q. In addition to the first actuator,
11 the controller handles of the Symphony system include a second actuator where a second button
12 that controls a second lever coupled to lines (filaments) that loop around the valve’s elongate
13 tubular member defining a lumen. The second button/lever/pin to which the second end of the
14 second filament line is coupled moves between a first (undepressed button) position where the
15 lumen of the lumen is constricted to a second (depressed button) position wherein the lumen is
16 less constricted and at least partially open.



(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)



(Annotated X-ray imaging of housing showing annotated first and second buttons, first and second levers, and first and second torsion springs.)

1 174. The hemostasis valves of the Symphony system practice the requirements of claim
2 10, including “a second biasing member configured to bias the second actuator to the first
3 position,” as can be seen in Exhibit Q. As with the first actuator, the Symphony system’s
4 hemostasis valve also includes a second torsion spring(s) that pushes against the second lever,
5 biasing the actuator to a first position (closed/constricted with an undepressed first button), as
6 can be seen above. There are two springs for each lever.

7 175. Defendant directly infringes claims of the ’921 Patent, including claims 1 and 10,
8 by making, using, selling, offering for sale, and/or importing Symphony system products, and
9 when persons under Defendant’s direction and control make, sell, offer to sell, import and/or use
10 (*e.g.*, to perform thrombectomy procedures utilizing the hemostasis valves) Symphony system
11 products.

12 176. Defendant induces infringement of claims of the ’921 Patent, including claims 1
13 and 10, by selling Symphony systems (and components thereof) and teaching or directing others,
14 including physicians, to use the Symphony systems that practice claims 1 and 10. Defendant
15 actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using
16 the Symphony system that include use of infringing hemostasis valves.

17 177. Defendant teaches and/or directs others to perform thrombectomy on, for example,
18 deep vein thrombosis using the Symphony system (and components thereof) and to use
19 hemostasis valves of the system. Defendant, for example, provides Instructions for Use that state
20 that the “Symphony Thrombectomy System is intended for: The non-surgical removal of fresh,
21 soft emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is
22 intended for use in the peripheral vasculature.” (Ex. B at 2.) The IFU further states that the
23 “Symphony Thrombectomy System is designed to remove thrombus/embolus (hereupon referred
24 to as ‘thrombus’ or ‘clot’) from the vasculature using controlled aspiration.” (*Id.* at 1.)
25 Defendant further provides brochures and other materials, including animations videos, that
26 detail how to use the TruVie Symphony system. (*See, e.g.*, [https://www.truvic.com/symphony-](https://www.truvic.com/symphony-product)
27 [product](https://www.truvic.com/symphony-product).) Upon information and belief, Defendant’s sales representatives additionally attend
28 procedures and instruct physicians regarding methods of using the TruVie Symphony system,

1 including on information and belief, methods of treating thrombi and emboli.

2 178. Defendant further engages in contributory infringement by offering to sell, selling,
3 and/or importing into the United States the Symphony system (and components thereof) of the
4 invention that is especially made or adapted for infringement of the claims of the '921 Patent
5 and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

6 179. Defendant has knowledge of the '921 Patent and its claims. Specifically, Inari
7 notified Defendant that the Symphony system infringes the '921 Patent, including claims 1 and
8 10, by letter dated April 24, 2024. Even more specifically, Inari explained that a teardown of
9 the hemostasis valves in the Symphony system showed that they infringe Inari's patents,
10 including claims 1 and 10 of the '921 Patent.

11 180. At a minimum, Defendant has notice of the '921 Patent through the filing of the
12 original Complaint.

13 181. Defendant has continued its infringing activities, despite knowledge of the '921
14 Patent (including knowledge from correspondence with Inari and through the original
15 Complaint), and such infringement has been and continues to be egregious and willful.

16 182. To the extent applicable, the requirements of 35 U.S.C. § 287(a) have been met
17 for the '921 Patent, including through the use of Inari's virtual marking website:
18 <https://www.inarimedical.com/inari-patents>.

19 183. Defendant's infringement has caused and will continue to cause Inari substantial
20 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

21 **COUNT 6: INFRINGEMENT OF THE '012 PATENT**

22 184. Inari realleges and incorporates by reference the preceding paragraphs as though
23 fully set forth herein.

24 185. The '012 Patent, titled "Hemostasis Valves and Methods of Use," is part of the
25 same family as the '921 Patent, and it shares the same specification. The '012 Patent discloses
26 improved hemostasis valves and methods of their use. (*See, e.g.*, Ex. H at Abstract, 1:64-2:5.)
27 Hemostasis valves are used to seal, e.g., to seal around catheters, in order to minimize blood loss,
28 and maintain sterility within the body, such as in a blood vessel. (*Id.* at 1:35-51.) This is critical

1 during surgical procedures to prevent patients from losing blood unnecessarily, to prevent air
 2 from entering into the vasculature (which can cause bubbles), and to reduce infection. (*See id.*
 3 at 1:24-32.) Improved hemostasis valves are important to maximize patient outcomes, including
 4 by providing ease of use (*e.g.*, one-handed use) for doctors and practitioners and effective
 5 sealing. (*See id.* at 1:51-60, 5:55-6:6.)

6 186. The '012 Patent discloses hemostasis valves as part of aspiration catheter systems,
 7 the catheters having an elongate flexible tube with a central lumen (an inner cavity through which
 8 something can be inserted) with a hemostasis valve on the proximal end of the catheter that
 9 includes a collapsible sidewall defining a valve lumen coupled to the central lumen of the
 10 catheter, and where the hemostasis valve has a constricting mechanism that includes an first
 11 actuator coupled to a first filament that is looped around the tubular sidewall of the valve lumen
 12 and further includes a spring that moves the actuator in a direction to pull the end portion of the
 13 filament to tighten the filament loop and constrict the lumen. (*See id.* at cl. 1, Fig. 7, 2:15-32.)
 14 Some embodiments disclosed by the '012 Patent have multiple actuators, *i.e.*, a first actuator
 15 comprising a first button and a second actuator comprising a second button. (*See id.* at cl. 1, cl.
 16 2, cl. 4.)

17 187. Defendant directly and indirectly infringes—literally and/or under the doctrine of
 18 equivalents—at least claim 1 of the '012 Patent by making, using, selling, offering for sale,
 19 and/or importing into the United States its Symphony system and components thereof.

20 188. The Symphony system practices each limitation of at least claim 1 of the '012
 21 Patent.

22 189. For example, claim 1 of the '012 Patent recites:

23 [1] An aspiration catheter, comprising:

24 an elongate, flexible tubular body, having a proximal end, a distal end and a
 25 central lumen;

26 (a) a collapsible tubular sidewall defining a valve lumen in communication with
 the central lumen; and

27 (b) a constricting mechanism having at least a first actuator, a first filament
 28 formed into a loop around the collapsible tubular sidewall, the filament having at
 least a first end portion extending away from the loop and connected to the first

1 actuator, and a first spring configured to move the first actuator in a direction that
2 pulls the first end portion such that a diameter of the valve lumen decreases in
3 response to reducing a diameter of the loop.


4 190. The Symphony system including the hemostasis valves practices the requirements
5 of claim 1, including the preamble, “[a]n aspiration catheter, comprising,” as can be seen in
6 Exhibit R. The TruVie Symphony system includes aspiration catheter systems for 24F and 16F
7 catheters:




14 (Screen capture from Symphony product video.)



24 (Ex. A at 2.)
25
26
27
28



(Annotated screen capture from Symphony product video.)



(Ex. A at 4 (annotations added) (showing a telescoping 16F and 24F catheter).)


191. The aspiration catheters of the Symphony system practice the requirements of claim 1, including “an elongate, flexible tubular body, having a proximal end, a distal end and a

central lumen,” as can be seen in Exhibit R. As discussed above, the 16F and 24F catheters of the Symphony system are flexible tubular bodies with a proximal end (coupled to the housing of the Symphony controller handles) and a distal end that can be advanced into the patient’s vasculature, with a central lumen.

192. The Symphony system including the hemostasis valves practices the requirements of claim 1, including “a hemostasis valve on the proximal end of the catheter, the hemostasis valve comprising,” as can be seen in Exhibit R. Specifically, the controller handles of the Symphony system include a hemostasis valve operated by blue buttons (in the 24F handle) and orange buttons (in the 16F handle) that include an elongate member (tubular member) that defines a lumen. The valve’s lumen is configured to receive a catheter and/or ProHelix device.



(Image of internal portion of housing with hemostasis valve.)



(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)

193. The Symphony Instructions For Use further teaches that the hemostasis valves of the Symphony systems are configured to slidably receive a catheter, *i.e.*, a 24F or 16F catheter, advanced using a dilator and/or a guide wire:

The TRUVIC™ Symphony™ Thrombectomy System is comprised of several devices:

- 24F Symphony Catheter
- 24F Symphony Dilator
- 24F Symphony Advance™ Long Dilator
- 24F Symphony ProHelix™
- 16F Symphony Catheter
- 16F Symphony Dilator
- 16F Symphony ProHelix
- TRUVIC Generator
- TRUVIC Canister
- TRUVIC Tubeset




Figure 1: Symphony Thrombectomy System components

(Ex. B at 1.)


PROCEDURE AND PREPARATION

1. Refer to **Warnings, Precautions, and Potential Adverse Events** prior to use.
2. Prepare and place an introducer sheath according to the manufacturer's Instructions for Use.
3. Prior to introducing the Symphony System, ensure an appropriate 0.035" guidewire is placed into the target vessel. When using the 24F Catheter with the 24F Dilator, a guidewire of at least 260cm length should be used. When using the 24F Advance Long Dilator or the Symphony 16F Catheter, a guidewire of at least 300cm length should be used.


- • • Press the Hemostasis buttons to open the hemostasis valve and insert the Dilator through the open Hemostasis Valve of the Handle. Advance the Dilator through the Catheter until Dilator hub snaps into the Retention Clip of the Handle.
- • • If desired, attach a manifold or syringe to the stopcock on the end of the Handle tubing labelled "MultiPort".
- • • Insert the Dilator and Catheter over the previously placed 0.035" guidewire into the introducer sheath.
- • • Advance the Symphony System until the tip of the Dilator is in the desired position in the selected vessel.
- • • Connect the Primary Tubing to the Handle tubing labelled "Vacuum".
- • • Attach the other end of the Primary Tubing to the TRUVIC Canister and ensure the stopcock on the Tubing is closed to the Generator.
- • • Release the Dilator by pressing the Retention Clip buttons on the Handle.
- • • When using a 24F Symphony System:
 - • • With the • • • Dilator, withdraw the Dilator approximately 1 cm then press the Hemostasis Valve buttons on the Handle to reduce friction and completely withdraw the Dilator while maintaining the Catheter and guidewire position.
 - ii. With the Advance Long Dilator, hold the dilator and guide wire in position and advance the catheter approximately 1 cm. Then press the Hemostasis Valve buttons on the Handle to reduce friction and advance the Catheter over the Dilator to the desired location. While pressing the Hemostasis Valve buttons, completely withdraw the Dilator and maintain the Catheter and guidewire position.
 - b. When using a 16F Symphony System, withdraw the Dilator approximately 1 cm then press the Hemostasis Valve buttons on the Handle to reduce friction and completely withdraw the dilator while maintaining the Catheter and guidewire position.

(Ex. B at 3-5.)


194. The Symphony system including the hemostasis valves practices the requirements of claim 1, including "a collapsible tubular sidewall defining a valve lumen in communication with the central lumen," as can be seen in Exhibit R. The hemostasis valve in each of the 24F and the 16F handles of the Symphony system has a tubular member with a collapsible tubular sidewall defining a lumen that is collapsible and can be constricted to seal the valve lumen (labeled as a tubular member) around a catheter and/or tool.



(Annotated image of internal portion of Symphony housing, including hemostasis valve with tubular member.)



(Image of internal portion of housing with hemostasis valve.)




(Annotated image of zoomed in internal portion of Symphony housing, including hemostasis valve with tubular member and lines (filaments) extending around the tubular member.)


195. The hemostasis valve is in communication with the aspiration catheter, as can be seen above in the Symphony Instructions For Use directing users to advance 24F and/or 16F catheters through a hemostasis valve in the handle.

196. The Symphony system including the hemostasis valves practices the requirements of claim 1, including “a constricting mechanism having at least a first actuator, a first filament formed into a loop around the collapsible tubular sidewall, the filament having at least a first end portion extending away from the loop and connected to the first actuator, and a first spring configured to move the first actuator in a direction that pulls the first end portion such that a diameter of the valve lumen decreases in response to reducing a diameter of the loop,” as can be seen in Exhibit R. The controller handles of the Symphony system each include a hemostasis valve with a constricting mechanism that constricts the valve lumen via a first actuator (a first button that controls a first lever and pin coupled to the end of lines (filaments) that loop around the valve’s elongate tubular member with a collapsible tubular sidewall defining a lumen). The first actuator comprising a first button/lever/pin to which the first end of the filament line is coupled, is movable between a first (undepressed button) position where the lumen of the lumen

is constricted to a second (depressed button) position wherein the lumen is less constricted and at least partially open.




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)




(Annotated image of zoomed in internal portion of Symphony housing, including hemostasis valve with tubular member and lines (filaments) extending around the tubular member.)


1 197. The Symphony system's hemostasis valves further include torsion spring(s)
2 configured to move the first actuator's lever and pin outward, thus pulling the first end portion
3 of the filament line, increasing the tension in the loop of the filament line around the valve lumen,
4 thus decreasing the diameter of the valve lumen by constricting the loop to decrease the diameter
5 of the loop. In operation, depressing the hemostasis valve button(s) of the Symphony system
6 controller handles pushes the lever(s) against the torsion spring, releasing tension on the
7 filaments wrapped around the lever pin(s), which decreases the constriction on the lumen of the
8 hemostasis valve. This allows the valve to at least partially open, permitting the introduction of
9 a catheter or other tool through the hemostasis valve. Releasing the button(s), causes the torsion
10 spring(s) to drive the lever outward, increasing tension on the filament lines, sealing the
11 hemostasis valve.



26 (Symphony handle with view down elongate member (lumen) of hemostasis valve with valve
27 constricted.)
28



(Internal image of hemostasis valve with filaments encircling and constricting elongate member.)



(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve open.)

198. Defendant directly infringes claims of the '012 Patent, including claim 1, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant's direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures using the hemostasis valves) Symphony system products.

199. Defendant induces infringement of claims of the '012 Patent, including claim 1 by selling Symphony systems (and components thereof) and teaching or directing others, including physicians, to use the Symphony systems that practice claim 1. Defendant actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using the Symphony system that include use of infringing hemostasis valves.

200. Defendant teaches and/or directs others to perform thrombectomy on, for example, deep vein thrombosis using the Symphony system (and components thereof) and to use hemostasis valves of the system. Defendant, for example, provides Instructions For Use that state that the "Symphony Thrombectomy System is intended for: The non-surgical removal of fresh, soft emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is intended for use in the peripheral vasculature." (Ex. B at 2.) The IFU further states that the "Symphony Thrombectomy System is designed to remove thrombus/embolus (hereupon referred to as 'thrombus' or 'clot') from the vasculature using controlled aspiration." (*Id.* at 1.) Defendant further provides brochures and other materials, including animations videos, that detail how to use the TruVie Symphony system. (See, *e.g.*, <https://www.truvic.com/symphony-product>.) Upon information and belief, Defendant's sales representatives additionally attend procedures and instruct physicians regarding methods of using the TruVie Symphony system, including on information and belief, methods of treating thrombi and emboli.

201. Defendant further engages in contributory infringement by offering to sell, selling, and/or importing into the United States the Symphony system (and components thereof), knowing that these are apparatuses for use in a patented process and constitute a material part of the invention that is especially made or adapted for infringement of the claims of the '012 Patent and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

202. Defendant's infringement is with knowledge of the '012 Patent and its claims. Specifically, as described above, Inari notified Defendant that the Symphony system might infringe the '012 Patent by letter dated September 29, 2023. Inari further explained, in its letter dated April 24, 2024, that a teardown of the hemostasis valves of the Symphony system demonstrated infringement, including infringement of claim 1 of the '012 Patent.

203. At a minimum, Defendant has notice of the '012 Patent through the filing of the original Complaint.

204. Defendant has continued its infringing activities, despite knowledge of the '012 Patent (including knowledge from correspondence with Inari and through the original Complaint), and such infringement has been and continues to be egregious and willful.

205. To the extent applicable, the requirements of 35 U.S.C. § 287(a) have been met for the '012 Patent, including through the use of Inari's virtual marking website: <https://www.inarimedical.com/inari-patents>.

206. Defendant's infringement has caused and will continue to cause Inari substantial and irreparable harm, entitling Inari to an award of damages and injunctive relief.

COUNT 7: INFRINGEMENT OF THE '291 PATENT

207. Inari realleges and incorporates by reference the preceding paragraphs as though fully set forth herein.

208. The '291 Patent, titled "Hemostasis Valves and Methods of Use," is part of the same family as the '921, and '012 Patents, and it shares the same specification. The '291 Patent discloses improved hemostasis valves and methods of their use. (*See, e.g.*, Ex. I at Abstract, 1:64-2:3.) Hemostasis valves are used to seal, e.g., to seal around catheters, in order to minimize blood loss, and maintain sterility within the body, such as in a blood vessel. (*Id.* at 1:35-50.) This is critical during surgical procedures to prevent patients from losing blood unnecessarily, to prevent air from entering into the vasculature (which can cause bubbles), and to reduce infection. (*See id.* at 1:24-32.) Improved hemostasis valves are important to maximize patient outcomes, including by providing ease of use (*e.g.*, one-handed use) for doctors and practitioners and effective sealing. (*See id.* at 1:51-60, 5:55-6:6.)

209. The '291 Patent discloses hemostasis valves having a support, an actuator mechanism that is moveable, an elongate tubular member with a collapsible tubular sidewall defining a lumen, where the hemostasis valve further has a constricting mechanism that includes an actuator with a first member (coupled to a first end of a filament) and a second member (coupled to a second end of the filament), where the actuator is biased by a spring to a first

1 position to constrict the elongate tubular member with the collapsible tubular sidewall defining
2 a valve lumen. (*See id.* at cl. 1, Fig. 7, 2:15-32.) Some embodiments disclosed by the '291
3 Patent have multiple members for the hemostasis valves, *i.e.*, a first actuator member and a
4 second actuator member used to move the hemostasis valve from a first (constricted) position to
5 a second (un-constricted) position. (*See id.* at cl. 1, cl. 2.)

6 210. Defendant directly and indirectly infringes—literally and/or under the doctrine of
7 equivalents—at least claim 1 of the '291 Patent by making, using, selling, offering for sale,
8 and/or importing into the United States its Symphony system and components thereof.

9 211. The Symphony system practices each limitation of at least claim 1 of the '291
10 Patent.

11 212. For example, claim 1 of the '291 Patent recites:

12 [1] A valve, comprising:

13 a support;

14 an actuator having at least a first member movably coupled to the support;

15 a collapsible tubular sidewall defining a lumen carried by the support;

16 a filament formed in a loop around the tubular sidewall, the filament having at
least a first end portion extending away from the loop to the first member; and

17 a spring configured to move the first member in a direction that pulls the first end
18 portion away from the tubular sidewall, reducing a diameter of the lumen in
response to reducing a diameter of the loop.


19 213. The hemostasis valves of the Symphony system practice the requirements of claim
20 1, including the preamble, “[a] valve, comprising,” as can be seen in Exhibit S. Specifically, the
21 controller handles of the Symphony system include a hemostasis valve operated by blue buttons
22 (in the 24F handle) and orange buttons (in the 16F handle). Documentation for the Symphony
23 system makes clear that the controller handles have a hemostasis valve, controlled by the buttons
24 on the handles, as can be seen in the excerpts and the teardown photos below.



(Ex. A at 2.)

High-Powered, Continuous Vacuum with Real-Time Case Assessment

BigShot™ Controller



(Annotated Ex. A at 6.)




(Image of internal portion of handle housing with hemostasis valve.)




(Image of internal portion of housing zoomed in on hemostasis valve.)

214. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “an actuator having at least a first member movably coupled to the support,” as can be seen in Exhibit S. Specifically, the controller handles of the Symphony system include a hemostasis valve operated by blue buttons (in the 24F handle) and orange buttons (in the 16F


handle) that include a clear plastic support that carries a tubular member and further has an actuator with a first and second member coupled to the support.



(Image of internal portion of housing with hemostasis valve.)




(Annotated X-ray imaging of housing showing annotated first and second buttons, first and second levers, and first and second torsion springs, as part of hemostasis valve in Symphony housing.)




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member and support.)

215. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “an actuator having at least a first member movably coupled to the support,” as can be seen in Exhibit S. Specifically, the controller handles of the Symphony system include a hemostasis valve having an actuator mechanism including a first member and a second member (a first that controls the first lever and a second button that controls the second lever coupled to the ends of lines (filaments) that loop around the valve’s elongate tubular member defining a lumen). The first member of the actuator is movably coupled to the clear plastic support, specifically the first lever and pin move inward if a first button is depressed, and are driven outward by a spring when the first button is not depressed. The first and second levers are fixed to the centerline of the support with an internal mount within the housing of the controller handle.




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)




(Annotated image of zoomed in internal portion of Symphony housing, including hemostasis valve with tubular member and lines (filaments) extending around the tubular member.)


1 216. In operation, depressing the hemostasis valve button(s) of the Symphony system
2 controller handles pushes the lever(s) against the torsion spring(s), releasing tension on the
3 filaments wrapped around the lever pin(s), which decreases the constriction on the lumen of the
4 hemostasis valve. This allows the valve to at least partially open, permitting the introduction of
5 a catheter or other tool through the hemostasis valve. Releasing the button(s), causes the torsion
6 spring(s) to drive the lever outward, increasing tension on the filament lines, sealing the
7 hemostasis valve.



8
9
10
11
12
13
14
15
16
17
18
19
20 (Symphony handle with view down tubular member (lumen) of hemostasis valve with valve
21 constricted.)
22
23
24
25
26
27
28




(Internal image of hemostasis valve with filaments encircling and constricting tubular member.)



(Symphony handle with view down tubular member (lumen) of hemostasis valve with valve open.)


217. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “a collapsible tubular sidewall defining a lumen carried by the support,” as can be seen in Exhibit S. The hemostasis valve in each of the 24F and the 16F handles of the Symphony system has a central tubular member defining a lumen that is collapsible and can be constricted to seal the valve (labeled as a tubular member).




(Annotated image of internal portion of Symphony housing, including hemostasis valve with tubular member.)




(Image of internal portion of housing with hemostasis valve.)




(Annotated image of zoomed in internal portion of Symphony housing, including hemostasis valve with tubular member and lines (filaments) extending around the tubular member.)



(Symphony handle with view down tubular member (lumen) of hemostasis valve with valve constricted.)



(Internal image of hemostasis valve with filaments encircling and constricting tubular member.)




(Symphony handle with view down tubular member (lumen) of hemostasis valve with valve open.)


218. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “a filament formed in a loop around the tubular sidewall, the filament having at least a first end portion extending away from the loop to the first member,” as can be seen in Exhibit S. As can be seen in the preceding paragraph, the hemostasis valves include a first filament and a second filament that are looped around the tubular sidewall of the tubular member of the

hemostasis valve, and the filament lines both have a first end portion that extends from the loop to couple to the first pin of the first lever of the first actuator member.

219. The hemostasis valves of the Symphony system practice the requirements of claim 1, including “a spring configured to move the first member in a direction that pulls the first end portion away from the tubular sidewall, reducing a diameter of the lumen in response to reducing a diameter of the loop,” as can be seen in Exhibit S. The hemostasis valve of the Symphony handles includes a first torsion spring that pushes against the first lever, biasing the first member to a first position (closed/constricted with an undepressed first button) and a second torsion spring that pushes against the second lever biasing the second member to the first position. There are two torsion springs for each lever.



(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)



(Annotated X-ray imaging of housing showing annotated first and second buttons, first and second levers, and first and second torsion springs.)

220. Defendant directly infringes claims of the '291 Patent, including claim 1, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant's direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures using the hemostasis valves) Symphony system products.

221. Defendant induces infringement of claims of the '291 Patent, including claim 1 by selling Symphony systems (and components thereof) and teaching or directing others, including physicians, to use the Symphony systems that practice claim 1. Defendant actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using the Symphony system that include use of infringing hemostasis valves.

222. Defendant teaches and/or directs others to perform thrombectomy on, for example, deep vein thrombosis using the Symphony system (and components thereof) and to use hemostasis valves of the system. Defendant, for example, provides Instructions for Use that state that the "Symphony Thrombectomy System is intended for: The non-surgical removal of fresh, soft emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is intended for use in the peripheral vasculature." (Ex. B at 2.) The IFU further states that the "Symphony Thrombectomy System is designed to remove thrombus/embolus (hereupon referred to as 'thrombus' or 'clot') from the vasculature using controlled aspiration." (*Id.* at 1.) Defendant further provides brochures and other materials, including animations videos, that detail how to use the TruVie Symphony system. (See, *e.g.*, <https://www.truvic.com/symphony->

1 [product](#).) Upon information and belief, Defendant's sales representatives additionally attend
2 procedures and instruct physicians regarding methods of using the Truvic Symphony system,
3 including on information and belief, methods of treating thrombi and emboli.

4 223. Defendant further engages in contributory infringement by offering to sell, selling,
5 and/or importing into the United States the Symphony system (and components thereof),
6 knowing that these are apparatuses for use in a patented process and constitute a material part of
7 the invention that is especially made or adapted for infringement of the claims of the '291 Patent
8 and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

9 224. Defendant's infringement is with knowledge of the '291 Patent and its claims.
10 Specifically, as described above, Inari notified Defendant that the Symphony system might
11 infringe the allowed claims of United States Patent Application 18/142,518, which has since
12 issued as the '291 Patent, by letter dated September 29, 2023. Inari further explained, in its letter
13 dated April 24, 2024, that a teardown of the hemostasis valves in the Symphony system showed
14 that they infringe Inari's patents, including claim 1 of the '291 Patent.

15 225. At a minimum, Defendant has notice of the '291 Patent through the filing of the
16 original Complaint.

17 226. Defendant has continued its infringing activities, despite knowledge of the '291
18 Patent (including knowledge from correspondence with Inari and through the original
19 Complaint), and such infringement has been and continues to be egregious and willful.

20 227. To the extent applicable, the requirements of 35 U.S.C. § 287(a) have been met
21 for the '291 Patent, including through the use of Inari's virtual marking website:
22 <https://www.inarimedical.com/inari-patents>.

23 228. The requirements of 35 U.S.C. § 154(d) have been met for the allowed claims of
24 the '518 Application from September 29, 2023, to the issuance of the '291 Patent.

25 229. Defendant's infringement has caused and will continue to cause Inari substantial
26 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

COUNT 8: INFRINGEMENT OF THE '580 PATENT

230. Inari realleges and incorporates by reference the preceding paragraphs as though fully set forth herein.

231. The '580 Patent is titled "Single Insertion Delivery System for Treating Embolism and Associated Systems and Methods." The '580 Patent discloses improved clot-removing methods for intravascular treatment of clot materials that solve problems with prior art clot-removal devices and methods. The '580 Patent solves these problems through its inventions and combination of inventions that include, for example, pre-charging a vacuum in a pressure source, connecting the pressure source to an elongated shaft, e.g., a catheter, to aspirate a first portion of a clot, opening an attachment member at the proximal end, and advancing an interventional device to engage a second portion of the clot remaining after the aspiration pass. (Ex. J at cl. 1.) The interventional device is a mechanical structure that can engage the clot material, and retain it, as the interventional device is withdrawn through the catheter. (*See id.*) The '580 Patent teaches that the using a guide aspiration catheter to advance the interventional device allows for multiple passes (repeated deployments and withdrawals) with the interventional device to remove more clot material. (*See id.* at Fig. 10, 3:45-62.)

232. The '580 Patent further solves problems in the art through a clot reservoir container with a removable filter. (*E.g., id.* at Fig. 3B, Fig. 3C, cls. 18-20.) The '580 Patent teaches that the clot reservoir and filter capture clot material within a housing, while filtered blood is allowed to flow through. (*Id.* at Figs. 3A-3C, 8:60-9:58.) This allows the treating physician to see the captured clot material to help determine whether additional passes are necessary and to remove clot that has been collected by removing and emptying the filter housing. (*Id.*)

233. Defendant directly and indirectly infringes—literally and/or under the doctrine of equivalents—at least claims 18 and 19 of the '580 Patent by making, using, selling, offering for sale, and/or importing into the United States its Symphony system and components thereof.

//

//

234. Specifically, claim 1 of the '580 Patent recites:

[1] A method for the intravascular treatment of clot material within a blood vessel, the method comprising:

positioning a distal portion of an elongated shaft proximate to the clot material within the blood vessel;

pre-charging a vacuum in a pressure source;

fluidly connecting the pressure source to the elongated shaft to apply the pre-charged vacuum to the elongated shaft to aspirate a first portion of the clot material into the elongated shaft;

unsealing an attachment member coupled to a proximal portion of the elongated shaft;

advancing an interventional device distally through the attachment member and the elongated shaft; and

engaging the interventional device with a second portion of the clot material remaining within the blood vessel.

235. Dependent claim 18 of the '580 Patent recites:

[18] The method of claim 1 wherein the method further comprises collecting at least some of the first portion of the clot material within a filter chamber fluidly coupled between the pressure source and the elongated shaft.

236. Dependent claim 19 of the '580 Patent recites:

[19] The method of claim 18 wherein the method further comprises removing a filter from within the filter chamber to provide access to the at least some of the first portion of the clot material.

237. Performing thrombectomy using the Truvic Symphony system including its ProHelix device practices each limitation of at least claims 1 (from which claims 18 and 19 depend), 18, and 19 of the '580 Patent, as can be seen in the '580 Patent claim chart, attached as Exhibit T.


238. To the extent the preamble of claim 1 is construed to be limiting, thrombectomy with the Symphony system, including thrombectomy using a ProHelix device, practices the requirements of the preamble, "[a] method for the intravascular treatment of clot material within a blood vessel, the method comprising," as can be seen in Exhibit T. For example, according to Truvic's Symphony Brochure, Symphony employs "next generation thrombus removal" with

“powerful, focused aspiration” for treating (*e.g.*, removing) clot material from within a blood vessel. (See Ex. A at 2-4.) The Symphony Instructions for Use further instruct that the system “is indicated for: [t]he non-surgical removal of fresh, soft emboli and thrombi from blood vessels.” (Ex. B at 12.) In addition, Symphony’s product website includes a video detailing a method of using the Symphony system to treat clot material within a blood vessel of a human patient using vacuum aspiration. (See <https://www.truvic.com/symphony-product>.)

239. Symphony’s Instructions for Use further teach users to advance a 16F or 24F ProHelix device within a catheter to engage the clot:

As needed, the Symphony ProHelix may be introduced through the Symphony Catheter to assist with thrombus removal. The Symphony ProHelix is manually advanced through the Symphony Catheter, remaining inside the Symphony Catheter during the procedure. During aspiration, the handle on the proximal end of the Symphony ProHelix is manually rotated, which rotates the tip of the Symphony ProHelix to facilitate thrombus removal through the Symphony Catheter.


(Ex. B at 1.) TruVic’s Symphony Brochure shows this as well:




(Ex. A at 10.)

240. Thrombectomy with the Symphony system, including thrombectomy using a ProHelix device, practices the limitations of claim 1, including “a positioning a distal portion of


an elongated shaft proximate to the clot material within the blood vessel,” as can be seen in Exhibit T. The Symphony system includes a 24F catheter (a “first catheter”) and a 16F catheter (a “second catheter”). (*Id.* at 2, 4.) These catheters can be used as aspiration catheters, and the TruVie Symphony system is “intended for use in the peripheral vasculature,” such as for deep vein thrombosis.



(Ex. A at 2 (annotations added).)




(Annotated screen capture from Symphony product video.)




(Ex. A at 4 (annotations added).)

241. In thrombectomy operations, the 16F second catheter can be advanced, including through the 24F first catheter and out of the 24F first catheter, through the vasculature of a patient over a guidewire and/or with a dilator positioned therein (as shown in the image below) until a distal portion of the 16F second catheter is positioned just proximal of clot material within a blood vessel of the vasculature. (See *id.* at 4.) The 24F catheter can also be advanced to a position proximal to the clot material within a blood vessel of the patient's vasculature. Upon information and belief, practitioners using the Symphony system are intended to and regularly do use this feature.



(Ex. A at 4 (annotations added).)



(Annotated screen capture from Symphony product video.)

242. Thrombectomy with the Symphony system, including thrombectomy with a ProHelix device, practices the limitations of claim 1, including “pre-charging a vacuum in a

pressure source,” as can be seen in Exhibit T. In the Symphony system, the 24F and 16F controller handles are coupled to a Truvic Generator and Truvic Canister, or another pressure source, which is a vacuum pressure source:

13. Confirm that both the 24F and 16F Handle vacuum levers are in the “OFF” position.





Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister


14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the “ON” position.

(Ex. B at 8.)

243. During thrombectomy using the Symphony system, the user initially sets the vacuum control lever on the 16F and/or 24F handles to the “OFF” position, which actuates a vacuum valve in the handle, ensuring that vacuum is not applied to the lumen of the 16F and/or 24F aspiration catheters:




(Annotated diagram of Symphony system.)



(Annotated image of Symphony housing (internal).)


Vacuum control valve in OFF position



(Annotated image of Symphony housing (internal).)

Vacuum control lever in "Off" position such that the clot canister is fluidly disconnected from the 16F catheter such that aspiration is not applied to the clot material

To vacuum pump aspiration source




(Annotated screen capture from Symphony product video.)


244. Thrombectomy with the Symphony system, including thrombectomy using a ProHelix device, practices the limitations of claim 1, including "fluidly connecting the pressure

source to the elongated shaft to apply the pre-charged vacuum to the elongated shaft to aspirate a first portion of the clot material into the elongated shaft,” as can be seen in Exhibit T. Specifically, during thrombectomy using the Symphony system, the user moves the vacuum lever on the 16F and/or 24F handles to the “ON” position, which actuates a valve in the handle, applying vacuum from the vacuum pump aspiration source (e.g., the Truvic Generator and Truvic Canister) to the lumen of the 16F and/or 24F aspiration catheters to aspirate clot:


Vacuum control lever in “On” position such that the clot canister is fluidly connected to the 24F catheter such that the clot material (deep vein thrombosis) is aspirated into the clot canister



(Annotated screen capture from Symphony product video.)



(Annotated image of Symphony housing (internal).)



(Annotated image of internal portion of controller handle housing.)

245. The Symphony IFU further teaches to fluidly connect the catheter to the stored vacuum by turning the vacuum lever to “on” to aspirate a portion of the clot.

12. Confirm the Handle vacuum lever is in the “OFF” position and open the stopcock on the Tubing.

13. Ensure the Generator is on and the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).

14. Confirm tip of the Symphony Catheter is in the desired location.

15. To begin aspiration, move the vacuum lever on the Handle to the “ON” position.

16. When unrestricted blood flow through the clot container and into the canister is observed, move the lever on the Handle to the “OFF” position.

17. If aspiration in another location is desired, reposition the tip of the Catheter using the Dilator, as necessary.

18. Confirm clot removal by briefly pressing the Vent Button to evacuate blood and visualize the clot in the container of the Handle.

(Ex. B at 5-6, 8-9.)

246. Thrombectomy with the Symphony system using a ProHelix device practices the limitations of claim 1, including “unsealing an attachment member coupled to a proximal portion of the elongated shaft,” and “advancing an interventional device distally through the attachment member and the elongated shaft,” as can be seen in Exhibit T. Specifically, when using the ProHelix device, Truvic teaches to push the buttons on the 24F or 16F Symphony Handle to release the hemostasis valve and then to advance the ProHelix device over the guidewire to the clot. (Ex. B at 2 (“Do not retract the Symphony ProHelix through the Hemostasis Valve on the Symphony Catheter unless the hemostasis valve is opened sufficiently to allow passage. Failing to actuate the Hemostasis Valve buttons while inserting or withdrawing a device through the Hemostasis Valve may damage the valve or the device.”), 5 (“Introduce the ProHelix over the previously placed 0.035” guidewire and through the Hemostasis Valve of the Handle until the handle of the ProHelix snaps into the Retention Clip of the Handle.”), 6 (“During ProHelix movement, press the Hemostasis Valve buttons on the Handle to reduce friction.”).)

247. Thrombectomy with the Symphony system using a ProHelix device practices the limitations of claim 1, including “engaging the interventional device with a second portion of the clot material remaining within the blood vessel,” as can be seen in Exhibit T. Specifically,

the IFU teaches users to employ a ProHelix device during procedures to engage a lot and clear clot obstructing the catheter tip, “[t]o resolve thrombus obstructing the Catheter tip, prepare and use the compatible Symphony ProHelix.”




Figure 4: ProHelix engaged with thrombus

(Ex. B at 5.) Truvic’s Symphony Brochure shows this as well, as does the Symphony video.



(Ex. A at 10; see also <https://vimeo.com/817718796>.)

248. Thrombectomy with the Symphony system, including thrombectomy using a ProHelix device, practices the limitations of claim 18, including “the method further comprises collecting at least some of the first portion of the clot material within a filter chamber fluidly

coupled between the pressure source and the elongated shaft.” Specifically, as can be seen in the images from page 4 of the IFU below, the Symphony system handle has a clot container with a filter chamber coupled between the Truvic Generator vacuum pump and the aspiration catheter that captures and filters clot material from blood during thrombectomy:

24F OR 16F SYMPHONY SYSTEM PREPARATION AND USE






Figure 3: Symphony Catheter Handle, labeled


(Ex. B at 4.) The fluid path from the aspiration catheter, through the clot canister to the vacuum pump is labeled in the annotated teardown image below:



(Annotated image of internal portion of controller handle housing.) The clot container includes a removable filter chamber including a housing and removable filter, as can be seen in the annotated images captured from of the Symphony video below:



(Annotated Symphony Thrombectomy System – Overview Animation Video at 0:45 (<https://www.truvic.com/symphony-product>).)



(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:55 (<https://www.truvic.com/symphony-product>).)

249. Thrombectomy with the Symphony system, including thrombectomy using a ProHelix device, practices the limitations of claim 19, including “wherein the method further comprises removing a filter from within the filter chamber to provide access to the at least some of the first portion of the clot material.” Specifically, as can be seen in the annotated images from the Symphony video below, Symphony system’s clot canister includes a removable filter chamber and a removable filter. To empty the collected clot from the clot canister, the operator removes the clot canister containing the clot and filter, and then removes the filter and the clot from the clot canister housing:



(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:18 (<https://www.truvic.com/symphony-product>).)



13 (Annotated Symphony Thrombectomy System – Overview Animation Video at 1:21
14 (<https://www.truvic.com/symphony-product>).)



25 (Symphony Thrombectomy System – Overview Animation Video at 1:21
26 (<https://www.truvic.com/symphony-product>).)

27 250. The clear clot container also allows visual access to the captured clot.

28

1 251. Defendant directly infringes claims of the '580 Patent, including claims 18 and 19
2 when Defendant or persons under its direction and control perform thrombectomy procedures
3 using Symphony system with a ProHelix device. For example, Defendant directly infringes
4 claims 18 and 19 when testing or using the Symphony system in patients.

5 252. Defendant induces infringement of claims of the '580 Patent, including claims 18
6 and 19 by selling Symphony systems (and components thereof) and teaching or directing others,
7 including physicians, to use the Symphony systems in a manner that practices the methods of
8 claims 18 and 19. Defendant actively induce users of the system, *e.g.*, doctors, to perform
9 thrombectomy procedures with the Truvic Symphony system using a ProHelix device in a
10 manner that practices the limitations of claims of the '580 Patent, including claims 18 and 19.
11 Defendant instructs and teaches users to perform methods that practice the limitations of claims
12 18 and 19 with knowledge and/or willful blindness that such acts constitute direct infringement
13 of the '580 Patent.

14 253. Defendant, for example, provides Instructions For Use that state that the
15 "Symphony Thrombectomy System is intended for: The non-surgical removal of fresh, soft
16 emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is intended
17 for use in the peripheral vasculature." (Ex. B at 2.) The IFU further states that the "Symphony
18 Thrombectomy System is designed to remove thrombus/embolus (hereupon referred to as
19 'thrombus' or 'clot') from the vasculature using controlled aspiration." (*Id.* at 1.) The IFU
20 further teaches users to employ a ProHelix device during procedures to engage a clot and clear
21 clot material obstructing the catheter tip, "[t]o resolve thrombus obstructing the Catheter tip,
22 prepare and use the compatible Symphony ProHelix."




Figure 4: ProHelix engaged with thrombus

(Ex. B at 5.)

254. Defendant further provides brochures and other materials, including animation videos, that detail how to use the TruVie Symphony system in a manner that practices claims of the '580 Patent, including claims 18 and 19. (See, e.g., <https://www.truvic.com/symphony-product>.) Upon information and belief, Defendant's sales representatives additionally attend procedures and instruct physicians regarding methods of using the TruVie Symphony system, including methods of treating clots use a ProHelix device that practice the claims of the '580 Patent.

255. Defendant further engages in contributory infringement by offering to sell, selling, and/or importing into the United States the Symphony system (and components thereof), knowing that these are apparatuses for use in a patented process and constitute a material part of the invention that is especially made or adapted for infringement of the claims of the '580 Patent and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

256. Defendant's infringement is with knowledge of the '580 Patent and its claims. Specifically, as described above, Inari notified Defendant, by letter dated September 29, 2023, that its products would infringe claims of United States Patent Application No. 17/498,642 ("the '642 Application"), when issued. Inari further attached the published version of this application (United States Published Application No. 2022/0240959) with claim 21, which later issued as claim 1 in identical or substantially identical form.

257. At a minimum, Defendant has notice of the '580 Patent through the filing of the First Amended Complaint, which was submitted to the Court just a few weeks after the '580 Patent issued.

258. Defendant has continued its infringing activities after the '580 Patent issued, despite knowledge of the '580 Patent (including knowledge from correspondence with Inari and from the First Amended Complaint), and such infringement has been and continues to be egregious and willful.

259. The requirements of 35 U.S.C. § 287(a) have been met for the '580 Patent. Because the '580 Patent contains only method claims, no marking is required.

260. The requirements of 35 U.S.C. § 154(d) have been met for the published claims of Publication No. 2022/0240959 from September 29, 2023, to the issuance of the '580 Patent.

261. Defendant's infringement has caused and will continue to cause Inari substantial and irreparable harm, entitling Inari to an award of damages and injunctive relief.

COUNT 9: INFRINGEMENT OF THE '384 PATENT

262. Inari realleges and incorporates by reference the preceding paragraphs as though fully set forth herein.

263. The '384 Patent, titled "Hemostasis Valves and Methods of Use," is part of the same family as the '921, '012, and '291 Patents, and shares the same specification. The '384 Patent discloses improved hemostasis valves and methods of their use. (*See, e.g.*, Ex. K at Abstract, 1:65-2:4.) Hemostasis valves are used to seal, *e.g.*, to seal around catheters, in order to minimize blood loss, and maintain sterility within the body, such as in a blood vessel. (*Id.* at 1:36-51.) This is critical during surgical procedures to prevent patients from losing blood unnecessarily, to prevent air from entering into the vasculature (which can cause bubbles), and to reduce infection. (*See id.* at 1:25-33.) Improved hemostasis valves are important to maximize patient outcomes, including by providing ease of use (*e.g.*, one-handed use) for doctors and practitioners and effective sealing. (*See id.* at 1:52-61, 5:55-6:6.)

264. The '384 Patent discloses hemostasis valves having an elongate tubular member defining a lumen, where the hemostasis valve further has a constricting mechanism that includes

1 a first filament extending in a first loop, a second filament extending in a second loop, and a pair
 2 of actuators that are movable between a first position to tension the first and second filament and
 3 constrict the lumen of the tubular member and a second position to loosen the first and second
 4 filament and partially open the lumen of the tubular member. (*See id.* at cl. 1, Fig. 8, 3:1-18.)
 5 The '384 Patent further is directed to embodiments where one of the actuators acts on a first end
 6 portion of the first filament and the other actuator acts on a second end portion of the first
 7 filament, and the second filament similarly has one end portion acted on by the first actuator and
 8 a second end portion acted on by a second actuator. (*See id.* at cl. 1, cl. 3.)

9 265. Defendant directly and indirectly infringes—literally and/or under the doctrine of
 10 equivalents—at least claims 1 and 3 of the '384 Patent by making, using, selling, offering for
 11 sale, and/or importing into the United States its Symphony system and components thereof.

12 266. Specifically, claim 1 recites:

13 [1] A valve assembly, comprising:

14 a tubular member defining a lumen;

15 a first filament extending in a first loop around the tubular member,
 16 wherein the first filament is flexible;

17 a second filament extending in a second loop around the tubular
 18 member, wherein the second filament is flexible;

a pair of actuators movable from a first position to a second position,
 wherein—;

19 the first filament includes a first portion operably acted upon by a
 20 first one of the actuators and a second portion operably acted upon
 21 by the second one of the actuators;

22 the second filament includes a first portion operably acted upon by
 23 the first one of the actuators and a second portion operably acted
 24 upon by the second one of the actuators;

25 in the first position, the actuators are positioned to tension the first
 26 filament and the second filament thereby decreasing a dimension
 27 of the first loop and a dimension of the second loop to constrict the
 28 lumen of the tubular member;

in the second position, the actuators are positioned to loosen the
 first filament and the second filament thereby permitting the tubular
 member to expand against the first loop and the second loop to
 increase the dimension of the first loop and the dimension of the
 second loop to at least partially open the lumen of the tubular

member; and

the actuators are biased to the first position.

267. Dependent claim 3 recites:

[3] The valve assembly of claim 1 wherein the first portion of the first filament is a first end portion of the first filament, wherein the second portion of the first filament is a second end portion of the first filament, wherein the first portion of the second filament is a first end portion of the second filament, and wherein the second portion of the second filament is a second end portion of the second filament.


268. The hemostasis valves of the Symphony system practice the elements of claim 1, including the preamble, “[a] valve assembly comprising,” as can be seen in Exhibit U. Specifically, the controller handles of the Symphony system include a hemostasis valve operated by blue buttons (in the 24F handle) and orange buttons (in the 16F handle). Documentation for the Symphony system makes clear that the controller handles have a hemostasis valve, controlled by the buttons on the handles, as can be seen in the excerpts and the teardown photos below.




(Ex. A at 2.)

High-Powered, Continuous Vacuum with Real-Time Case Assessment

BigShot™ Controller



(Annotated Ex. A at 6.)



15 (Image of internal portion of housing with hemostasis valve.)




28 (Image of internal portion of housing zoomed in on hemostasis valve.)


1 269. The Symphony system practices the limitations of claim 1, including “a tubular
2 member defining a lumen,” as can be seen in Exhibit U. Specifically, the controller handles of
3 the Symphony system include a hemostasis valve operated by blue buttons (in the 24F handle)
4 and orange buttons (in the 16F handle) that include an elongate tubular member that defines a
5 lumen, as can be seen in the teardown images below.



18 (Image of internal portion of housing with hemostasis valve.)
19
20
21
22
23
24
25
26
27
28




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)




(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve open.)

270. Thrombectomy with the Symphony system practices the limitations of claim 1, including “a first filament extending in a first loop around the tubular member, wherein the first filament is flexible,” as can be seen in Exhibit U. Specifically, the controller handles of the Symphony system include a hemostasis valve with an active tensioning mechanism where a first and second button control first and second levers and first and second pins coupled to first and second lines (filaments) that loop around the valve’s elongate tubular member defining a lumen, and the first and second filaments forming loops are flexible, as can be seen in the teardown images below. The first and second filaments are braided filament lines, which are flexible.




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)



(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve constricted.)



(Internal image of hemostasis valve with filaments encircling and constricting elongate member.)




(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve open.)

271. Thrombectomy with the Symphony system practices the limitations of claim 1, including “a second filament extending in a second loop around the tubular member, wherein the second filament is flexible,” as can be seen in Exhibit U, and in the preceding limitation. The first and second filaments are braided filament lines, which are flexible.

272. The Symphony system practices the limitations of claim 1, including “a pair of actuators movable from a first position to a second position,” as can be seen in Exhibit U. Specifically, the controller handles of the Symphony system include a hemostasis valve with an active tensioning mechanism with two actuators where a first and second button control first and second levers and first and second pins coupled to lines (filaments) that loop around the valve’s elongate tubular member defining a lumen. The first actuator includes the first button/lever/pin to which the first ends of each of the first and the second filaments (lines) are wrapped around and the second actuator includes the second button/lever/pin to which the second ends of each of the first and the second filaments (lines) are wrapped around. The first and second actuators move between a first (undepressed button) position where the lumen of the valve is constricted

to a second (depressed button) position wherein the lumen is less constricted and at least partially open, as can be seen in the teardown images below.




(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)

273. The Symphony system practices the limitations of claim 1, including “the first filament includes a first portion operably acted upon by a first one of the actuators and a second portion operably acted upon by a second one of the actuators,” as can be seen in Exhibit U. Specifically, as can be seen in the teardown image above, the first end portion of the first filament is coupled to and acted upon by the first actuator (button/lever/pin), and the second end portion of the first filament is coupled to and acted upon by the second actuator (button/lever/pin).


274. The Symphony system practices the limitations of claim 1, including “a second filament includes a first portion operably acted upon by the first one of the actuators and a second portion operably acted upon by the second one of the actuators,” as can be seen in Exhibit U. Specifically, as can be seen in the teardown image above, the first end portion of the second filament is coupled to and acted upon by the first actuator (button/lever/pin), and the second end

1 portion of the second filament is coupled to and acted upon by the second actuator
2 (button/lever/pin).

3 275. The Symphony system practices the limitations of claim 1, including “in the first
4 position, the actuators are positioned to tension the first filament and the second filament thereby
5 decreasing the dimension of the first loop and a dimension of the second loop to constrict the
6 lumen of the tubular member,” as can be seen in Exhibit U. Specifically, when the actuators are
7 in the first (undepressed buttons) position, the actuators tension the first filament and the second
8 filament, decreasing the dimension of the first loop in the first filament and the second loop in
9 the second filament to constrict the tubular member, as can be seen in the teardown images
10 below.




11
12
13
14
15
16
17
18
19
20
21
22
23
24 (Symphony handle with view down elongate member (lumen) of hemostasis valve with
25 valve constricted.)
26
27
28




(Internal image of hemostasis valve with filaments encircling and constricting elongate member.)

276. The Symphony system practices the limitations of claim 1, including “in the second position, the actuators are positioned to loosen the first filament and the second filament thereby permitting the tubular member to expand against the first loop and the second loop to increase the dimension of the first loop and the dimension of the second loop to at least partially open the lumen of the tubular member,” as can be seen in Exhibit U. Specifically, when the actuators are in the second (depressed buttons) position, the actuators push and loosen tension on the first filament and the second filament, allowing the dimension of the first loop in the first filament and the second loop in the second filament to increase and at least partially open the tubular member, as can be seen in the teardown images below.




(Symphony handle with view down tubular member (lumen) of hemostasis valve with valve open.)


277. The Symphony system practices the limitations of claim 1, including “the actuators are biased to the first position,” as can be seen in Exhibit U. Specifically, the first and the second actuators are driven outward/biased to the first (constricted, undepressed button) position by first and second sets of torsion springs that drive the first lever and the second lever outward, as can be seen in the teardown images below.



(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)



(Annotated X-ray imaging of housing showing annotated first and second buttons, first and second levers, and first torsion springs and second torsion springs.)




(Symphony handle with view down elongate member (lumen) of hemostasis valve with valve constricted.)




(Internal image of hemostasis valve with filaments encircling and constricting elongate member.)

278. Thrombectomy with the Symphony system practices the limitations of claim 3, including “wherein the first portion of the first filament is a first end portion of the first filament, wherein the second portion of the first filament is a second end portion of the first filament,” as can be seen in Exhibit U. Specifically, the first end portions of the first and second filaments are wrapped around and acted upon by the first actuator, as can be seen in the teardown images below.



(Annotated image of internal portion of Symphony housing, including hemostasis valve with elongate tubular member.)



15 (Image of internal portion of housing with hemostasis valve.)



28 (Image of internal portion of housing zoomed in on hemostasis valve.)

279. Thrombectomy with the Symphony system practices the limitations of claim 3, including wherein the first portion of the second filament is a first end portion of the second filament, and wherein the second portion of the second filament is a second end portion of the second filament,” as can be seen in Exhibit U. Specifically, the second end portions of the first and second filaments are wrapped around and acted upon by the second actuator, as can be seen in the teardown images above.

280. Defendant directly infringes claims of the ’384 Patent, including claims 1 and 3, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant’s direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures using the hemostasis valves) Symphony system products.

281. Defendant induces infringement of claims of the ’384 Patent, including claims 1 and 3, by selling Symphony systems (and components thereof) and teaching or directing others, including physicians, to use the Symphony products that practice claims 1 and 3. Defendant actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using the Symphony system that include use of infringing hemostasis valves.

282. Defendant teaches and/or directs others to perform thrombectomy on, for example, deep vein thrombosis using the Symphony system (and components thereof) and to use hemostasis valves of the system. Defendant, for example, provides Instructions for Use that state that the “Symphony Thrombectomy System is intended for: The non-surgical removal of fresh, soft emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is intended for use in the peripheral vasculature.” (Ex. B at 2.) The IFU further states that the “Symphony Thrombectomy System is designed to remove thrombus/embolus (hereupon referred to as ‘thrombus’ or ‘clot’) from the vasculature using controlled aspiration.” (*Id.* at 1.) Defendant further provides brochures and other materials, including animations videos, that detail how to use the TruViv Symphony system. (See, *e.g.*, <https://www.truvic.com/symphony-product>.) Upon information and belief, Defendant’s sales representatives additionally attend procedures and instruct physicians regarding method of using the TruViv Symphony system,

1 including on information and belief, methods of treating thrombi and emboli.

2 283. Defendant further engages in contributory infringement by offering to sell, selling,
3 and/or importing into the United States the Symphony system (and components thereof),
4 knowing that these are apparatuses for use in a patented process and constitute a material part of
5 the invention that is especially made or adapted for infringement of the claims of the '384 Patent
6 and not a staple article or commodity of commerce suitable for substantial non-infringing uses.

7 284. At a minimum, Defendant has notice of the '384 Patent through the filing of the
8 Second Amended Complaint. On information and belief, Defendant has had knowledge of the
9 '384 Patent via monitoring and investigation of Inari's patent portfolio, including in response to
10 the notice letters provided by Inari regarding many other patents, including family members of
11 the '384 Patent.

12 285. Defendant has continued its infringing activities after the '384 Patent issued,
13 despite knowledge of the '384 Patent (including from the Second Amended Complaint), and
14 such infringement has been and continues to be egregious and willful.

15 286. Defendant's infringement has caused and will continue to cause Inari substantial
16 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

17 **COUNT 10: INFRINGEMENT OF THE '669 PATENT**

18 287. Inari realleges and incorporates by reference the preceding paragraphs as though
19 fully set forth herein.

20 288. The '669 Patent, titled "Single Insertion Delivery System for Treating Embolism
21 and Associated Systems and Methods," is part of the same family as the '580 Patent and shares
22 the same specification. The '669 Patent discloses improved clot-removing devices for
23 intravascular treatment of clot materials that solve problems with prior art clot-removal devices
24 and methods. The '669 Patent solves these problems through its inventions and combination of
25 inventions that include, for example, a vacuum source that is coupled to both an elongated shaft,
26 *e.g.*, a catheter, and a filter chamber via a flow controller and a first fluid path. (Ex. L at cl. 15.)
27 The filter chamber includes a housing and filter, where the housing further includes a first port
28 coupled to the catheter and a second port coupled to the vacuum source, and the filter is in the

1 housing along a first fluid path that includes a flow controller to couple the filter chamber and
 2 catheter. (*Id.*) A hemostasis valve is coupled to the catheter along a second fluid path that is at
 3 least partially different than the first, where the hemostasis valve inhibits flow along the second
 4 path when an interventional device is inserted. (*See id.*, Fig. 10, 3:53-4:3.)

5 289. The '669 Patent further solves problems in the art through a filter chamber, or clot
 6 reservoir container, having a removable filter. (*E.g., id.* at Fig. 3B, Fig. 3C, cl. 22.) The '669
 7 Patent teaches that the filter chamber/clot reservoir and filter capture clot material within a
 8 housing, while filtered blood is allowed to flow through. (*Id.* at Fig. 3A, Fig. 3B, Fig. 3C, 8:60-
 9 9:60.) A filter that is removable from within the housing allows the treating physician to
 10 visualize the captured clot material to help determine whether additional passes are necessary
 11 and to remove clot that has been collected by removing and emptying the filter housing. (*Id.*)
 12 As disclosed in other Inari patents, filtered blood can also be reintroduced to the patient's
 13 vasculature.

14 290. Defendant directly infringes and indirectly infringes—literally and/or under the
 15 doctrine of equivalents—at least claim 15 of the '669 Patent by making, using, selling, offering
 16 for sale, and/or importing into the United States its Symphony system and components thereof.

17 291. Specifically, claim 15 of the '669 Patent recites:

18 [15] An aspiration system, comprising:

19 a vacuum source;

20 a catheter fluidically coupled to the vacuum source via a first fluid path;

21 a filter chamber along the first fluid path and spaced apart from the
 22 vacuum source, wherein the filter chamber comprises a housing and a
 filter within the housing, and wherein the housing includes—;

23 a first port configured to be fluidically coupled to the catheter; and

24 a second port configured to be fluidically coupled to the vacuum
 source; and

25 wherein the filter is in the housing along the first fluid path between
 the first port and the second port

26 a flow controller fluidically coupling the filter chamber to the catheter,
 27 wherein the flow controller is along the first fluid path between the
 28 filter chamber and the catheter; and

1 a hemostasis valve fluidically coupled to the catheter along a second
2 fluid path at least partially different than the first fluid path, wherein
3 the hemostasis valve is configured to maintain hemostasis by inhibiting
4 proximal fluid flow along the second fluid path when an interventional
5 device is inserted through the hemostasis valve and the catheter.

6 292. The TruVic Symphony system practices each limitation of at least claim 15 of the
7 '669 Patent, as can be seen in the '669 Patent claim chart, attached as Exhibit V.

8 293. To the extent the preamble of claim 15 is construed to be limiting, the Symphony
9 system practices the requirements of the preamble, "[a]n aspiration system, comprising," as can
10 be seen in Exhibit V. For example, according to TruVic's Symphony Brochure, the Symphony
11 system allows for "[p]owerful, focused Aspiration" that "[m]aximize[s] thrombus removal with
12 high-powered, on-demand, continuous aspiration and in-hand TruView™ clot capture." (Ex. A
13 at 2.) The Symphony Instructions for Use further states that "[t]he Symphony Catheter targets
14 aspiration from the TRUVIC Generator directly to the thrombus. The Symphony ProHelix may
15 be used to facilitate aspiration and removal of the thrombus through the Symphony Catheter."
16 (Ex. B at 1.) In addition, Symphony's product website includes a video detailing a method of
17 using the Symphony system to treat clot material within a blood vessel of a human patient using
18 vacuum aspiration. (See <https://www.truvic.com/symphony-product>.)

19 294. The Symphony system practices the limitations of claim 15, including "a vacuum
20 source," as can be seen in Exhibit V. In the Symphony system, the 24F and/or 16F controller
21 handles (shown in an optional telescoping configuration below) are coupled to a TruVic
22 Generator and TruVic Canister, or another pressure source, which is a vacuum source.
23
24
25
26
27
28




Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister

14. Turn on the Generator and ensure that the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU).
15. Open the stopcock on the Tubeset to allow vacuum to both the 24F and 16F Systems and ensure no leaks are detected.
16. Confirm tip of the 16F Symphony Catheter is in the desired location under fluoroscopy.
17. To begin aspiration, move the vacuum lever on the 16F Handle to the "ON" position.

(Ex. B at 8.)

295. Symphony's product website includes a video detailing a method of using the Symphony system to treat clot material within a blood vessel of a human patient using the Truvic Generator and Truvic Canister as a vacuum source. (See <https://www.truvic.com/symphony-product>.)

296. The Symphony system practices the limitations of claim 15, including "a catheter fluidically coupled to the vacuum source via a first fluid path," as can be seen in Exhibit V. Specifically, as can be seen in the images from page 8 of the IFU below, the Symphony system includes a catheter coupled to the Truvic Generator and Truvic Canister via the first fluid path through the Symphony system 16F and/or 24F handles (the BigShot Controller Handles).






Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister

(Ex. B at 8 (annotated) (showing a telescoping configuration).)



(Annotated Symphony Thrombectomy System – Overview Animation Video at 0:57 (<https://www.truvic.com/symphony-product>)).



(Annotated image of internal portion of controller handle housing with flow path.)

297. The Symphony system practices the limitations of claim 15, including “a filter chamber along the first fluid path and spaced apart from the vacuum source, wherein the filter chamber comprises a housing and a filter within the housing,” as can be seen in Exhibit V. Specifically, as can be seen from the images above and from page 4 of the IFU below, the Symphony system handle has a clot container with a filter chamber coupled to the Truvic Generator and Truvic Canister and the aspiration catheter that captures and filters clot material from blood during thrombectomy.




Figure 3: Symphony Catheter Handle, labeled

(Ex. B at 4.)

298. As can be seen from the images from page 8 of the IFU below, the Symphony system includes a filter chamber along the first fluid path that is spaced apart from the TruVic Generator and TruVic Canister (e.g., vacuum source).





Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister

(Ex. B at 8 (annotated).)

299. As can be further seen from the annotated images from the Symphony video below, the Symphony system includes a filter chamber that has a housing and a filter within it.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:15 (<https://www.truvic.com/symphony-product>).)




(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:21 (<https://www.truic.com/symphony-product>).)

300. The Symphony system practices the limitations of claim 15, including “wherein the housing includes—a first port configured to be fluidically coupled to the catheter,” as can be seen in Exhibit V. Specifically, the clot canister of the Symphony system includes a first port that is fluidly connected to the aspiration catheter, as shown in the teardown image below.




(Annotated image of internal portion of controller handle housing).

301. The Symphony system practices the limitations of claim 15, including “wherein the housing includes—...a second port configured to be fluidically coupled to the vacuum source,” as can be seen in Exhibit V. Specifically, the clot canister of the Symphony system includes a second port that is fluidly connected to the Truvic Generator and Truvic Canister (*e.g.*, vacuum source), as shown in the teardown image below.



(Annotated image of internal portion of controller handle housing).

302. As can be seen from the images from page 4 of the IFU below, the Symphony system includes a vacuum port that fluidly connects the housing and vacuum source.




(Ex. B at 4.)

303. Thrombectomy with the Symphony system, including thrombectomy using a ProHelix device, practices the limitations of claim 15, including “wherein the filter is in the housing along the first fluid path between the first port and the second port,” as can be seen in Exhibit V. Specifically, the clot canister of the Symphony system includes a removable filter that is along the first fluid path between the first port that fluidly couples the catheter and the second port that fluidly couples the vacuum source, as shown in the annotated images from the Symphony video below. The housing of the Symphony product receives the clot and blood from the human patient via the first port fluidly coupled to aspiration catheter, where the blood is filtered out of the housing via the second port that is fluidly coupled to the vacuum source.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 0:57 (<https://www.truvic.com/symphony-product>).)

304. The filter contained within the housing is along the first fluid path.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:21 (<https://www.truvic.com/symphony-product>).)


305. The Symphony system practices the limitations of claim 15, including “a flow controller fluidically coupling the filter chamber to the catheter, wherein the flow controller is along the first fluid path between the filter chamber and the catheter,” as can be seen in Exhibit V. Specifically, as can be seen from the images from page 4 of the IFU below the Symphony system handle includes a vacuum control valve and vacuum lever (*e.g.*, flow controller).



(Ex. B at 3.) As can be seen from the teardown image below, the flow controller is along the first fluid path and couples the filter chamber to the aspiration catheter.



(Annotated image of internal portion of controller handle housing.)




(Annotated image of internal portion of the controller housing with vacuum lever.)

306. As shown in the Symphony system animation video, when the vacuum lever is moved to an “On” position, the clot flows from the human patient, through the aspiration catheter along the first flow path to the housing of the filter chamber.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 0:55 (<https://www.truvic.com/symphony-product>).)

307. The Symphony system practices the limitations of claim 15, including “a hemostasis valve fluidically coupled to the catheter along a second fluid path at least partially different than the first fluid path, wherein the hemostasis valve is configured to maintain hemostasis by inhibiting proximal fluid flow along the second fluid path when an interventional device is inserted through the hemostasis valve and the catheter,” as can be seen in Exhibit V. Specifically, as can be seen from the IFU and the teardown image below, the hemostasis valve of the Symphony system is fluidically coupled to the aspiration catheter along a second fluid path, that is at least partially different than the first fluid path (e.g., the portion of the second fluid path running from the hemostasis valve toward the aspiration catheter).



(Annotated image of internal portion of controller handle housing.)



(Ex. B. at 4)

308. The IFU teaches that the ProHelix device (the interventional device) can be inserted through the hemostasis valve and the catheter to reach the clot, demonstrating that the hemostasis valve is configured to maintain hemostasis by inhibiting proximal fluid flow along the second path (through the hemostasis valve) when an interventional device, such as a ProHelix is inserted through the valve and to the catheter.




Figure 4: ProHelix engaged with thrombus

(Ex. B at 5.) Moreover, the buttons for the hemostasis valve on the 24F or 16F Symphony handle are configured to be pushed to release the hemostasis valve and then to advance a device, for example a ProHelix device (the interventional device), over the guidewire to the clot. (Ex. B at 5 (“Introduce the ProHelix over the previously placed 0.035” guidewire and through the Hemostasis Valve of the Handle until the handle of the ProHelix snaps into the Retention Clip of the Handle.”), 6 (“During ProHelix movement, press the Hemostasis Valve buttons on the Handle to reduce friction.”).) The buttons are configured to be released to seal the valve around the inserted device, such as a ProHelix, so that the Symphony hemostasis valve inhibits fluid flow along the second fluid path by clamping down on the inserted ProHelix device.

309. Defendant directly infringes claims of the ’669 Patent, including claim 15, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant’s direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures) Symphony system products, such as with a ProHelix device.

310. Defendant induces infringement of claims of the ’669 Patent, including claim 15, by selling Symphony systems and teaching or directing others, including physicians, to use the

1 Symphony products that practice claim 15. Defendant actively induces users of the system, *e.g.*,
2 doctors, to perform thrombectomy procedures using the Symphony system.

3 311. Defendant teaches and/or directs others to perform thrombectomy on, for example,
4 deep vein thrombosis using the Symphony system (and components thereof) and to use
5 hemostasis valves of the system. Defendant, for example, provides Instructions for Use that state
6 that the “Symphony Thrombectomy System is intended for: The non-surgical removal of fresh,
7 soft emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is
8 intended for use in the peripheral vasculature.” (Ex. B at 2.) The IFU further states that the
9 “Symphony Thrombectomy System is designed to remove thrombus/embolus (hereupon referred
10 to as ‘thrombus’ or ‘clot’) from the vasculature using controlled aspiration.” (*Id.* at 1.)
11 Defendant further provides brochures and other materials, including animations videos, that
12 detail how to use the TruVie Symphony system. (See, *e.g.*, [https://www.truvic.com/symphony-](https://www.truvic.com/symphony-product)
13 [product](https://www.truvic.com/symphony-product).) Upon information and belief, Defendant’s sales representatives additionally attend
14 procedures and instruct physicians regarding method of using the TruVie Symphony system,
15 including on information and belief, methods of treating thrombi and emboli.

16 312. Defendant further engages in contributory infringement by offering to sell, selling,
17 and/or importing into the United States the Symphony system, knowing that these are
18 apparatuses for use in a patented process and constitute a material part of the invention that is
19 especially made or adapted for infringement of the claims of the ’669 Patent and not a staple
20 article or commodity of commerce suitable for substantial non-infringing uses.

21 313. At a minimum, Defendant has notice of the ’669 Patent through the filing of the
22 Second Amended Complaint. On information and belief, Defendant has had knowledge of the
23 ’669 Patent via monitoring and investigation of Inari’s patent portfolio, including in response to
24 the notice letters provided by Inari regarding many other patents, including family members of
25 the ’669 Patent.

26 314. Defendant has continued its infringing activities after the ’669 Patent issued,
27 despite knowledge of the ’669 Patent (including from the Second Amended Complaint), and
28 such infringement has been and continues to be egregious and willful.

1 315. Defendant's infringement has caused and will continue to cause Inari substantial
2 and irreparable harm, entitling Inari to an award of damages and injunctive relief.

3 **COUNT 11: INFRINGEMENT OF THE 12-'333 PATENT**

4 316. Inari realleges and incorporates by reference the preceding paragraphs as though
5 fully set forth herein.

6 317. The 12-'333 Patent, titled "Single Insertion Delivery System for Treating
7 Embolism and Associated Systems and Methods," is part of the same family as the '580 Patent
8 and '669 Patent and shares the same specification. The 12-'333 Patent discloses improved clot-
9 removing devices for intravascular treatment of clot materials that solve problems with prior art
10 clot-removal devices and methods. The 12-'333 Patent solves these problems through its
11 inventions and combination of inventions that include, for example, a clot collection reservoir
12 with a partially transparent housing that defines a chamber, a first port connected to a catheter,
13 and a second port connected to an aspiration source that generates negative pressure in the
14 chamber, where the chamber includes a filter. Ex. W at cl. 1. The filter is substantially
15 cylindrical and prevents clot material and not the blood (drawn in through the catheter) from
16 passing through the filter body and out through the second port. *Id.* The 12-'333 Patent teaches
17 that a transparent housing allows the doctor to see the clot material so they can at least partially
18 determine whether additional passes with an interventional device are needed to remove more
19 clot material. *Id.* at 9:57-64.

20 318. The 12-'333 Patent further solves problems in the art through a clot reservoir
21 container with a removable filter. *E.g., id.* at Fig. 3B, Fig. 3C, cl. 1. The 12-'333 Patent teaches
22 that the filter chamber/clot reservoir and filter capture clot material within a housing, while
23 filtered blood is allowed to flow through. *Id.* at Fig. 3A, Fig. 3B, Fig. 3C, 9:40-64. This also
24 allows the treating physician to visualize the captured clot material to help determine whether
25 additional passes are necessary and to remove clot material that has been collected by removing
26 and emptying the filter housing. *Id.* As disclosed in other Inari patents, the filtered blood can
27 also be reintroduced to the patient's vasculature to further mitigate blood loss during procedures.

28 319. Defendant directly and indirectly infringes—literally and/or under the doctrine of

equivalents—at least claim 1 of the 12-’333 Patent by making, using, selling, offering for sale, and/or importing into the United States its Symphony system and components thereof.

320. Specifically, claim 1 of the 12-’333 Patent recites:

[1] A clot collection reservoir, comprising:

a housing defining a sealed chamber and having a first housing end portion and a second housing end portion opposite the first housing end portion;

a first port configured to be fluidly coupled to an aspiration catheter, wherein the first port is positioned proximate to the first housing end portion and provides a first fluid path to the chamber;

a second port configured to be fluidly coupled to an aspiration source, wherein the second port provides a second fluid path from the chamber; and

a filter removably positioned within the chamber, wherein the filter has a substantially cylindrical shape extending from a first filter end portion to a second filter end portion, and wherein the filter extends continuously about the first filter end portion such that the filter body encloses an interior region around the second port;

wherein the aspiration source is configured to generate negative pressure in the chamber via the second port to (a) draw blood and clot material from the aspiration catheter through the first port into the chamber and (b) draw blood through the filter into the interior region and through the second port;


wherein the filter is configured to inhibit the clot material from passing through the filter into the interior region and through the second port; and

wherein the housing is at least partially transparent to permit visualization of the clot material in the chamber outside the interior region.


321. The Truvic Symphony system practices each limitation of at least claim 1 of the 12-’333 Patent, as can be seen in the 12-’333 Patent claim chart, attached as Exhibit X.

322. To the extent the preamble of claim 1 is construed to be limiting, the Symphony system practices the requirements of the preamble, “[a] clot collection reservoir, comprising,” as can be seen in Exhibit X. In the Symphony system, the 24F and 16F controller handles include a clot collection reservoir. For example, according to the Symphony Instructions for Use the Symphony system includes a clot collection reservoir where a user can “[c]onfirm clot removal

by briefly pressing the Vent Button to evacuate blood and visualize the clot in the container of the Handle.” Ex. B at 5. The IFU depicts the clot collection reservoir of the Symphony system, as shown below.



(*Id.* at 4.) TruVic’s Symphony Brochure shows the clot collection reservoir as well.




(Ex. A at 6.)

323. The Symphony system practices the limitations of claim 1, including “a housing defining a sealed chamber and having a first housing end portion and a second housing end portion opposite the first housing end portion,” as can be seen in Exhibit X. The clot collection reservoir of the Symphony system includes a housing that defines a sealed chamber (*e.g.*, the interior of the housing) with a first housing end portion and a second housing end portion

opposite the first, as can be seen in the annotated images of the Symphony overview animation video below.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:21 (<https://www.truic.com/symphony-product>).)



(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:57 (<https://www.truic.com/symphony-product>).)


324. The Symphony system practices the limitations of claim 1, including “a first port configured to be fluidly coupled to an aspiration catheter, wherein the first port is positioned proximate to the first housing end portion and provides a first fluid path to the chamber,” as can

be seen in Exhibit X. Specifically, the Symphony 24F and 16F controller handles include a clot collection reservoir with a first port fluidly coupled to an aspiration catheter, providing a fluid flow path to the chamber, as shown in the annotated teardown image below.




(Annotated image of internal portion of controller handle housing)

325. The first port of the clot collection reservoir is positioned proximate to the first housing end portion such that fluid flows through the first port to the chamber, as shown in the annotated images of the Symphony overview animation video below.



(Annotated Symphony Thrombectomy System – Overview Animation Video at 0:57 (<https://www.truvic.com/symphony-product>).)

326. The Symphony system practices the limitations of claim 1, including “a second port configured to be fluidly coupled to an aspiration source, wherein the second port provides a second fluid path from the chamber,” as can be seen in Exhibit X. Specifically, the Symphony system 24F and 16F handles (BigShot Controller handles) include a clot collection reservoir with a second port fluidly coupled to an aspiration source (the Truvic Generator and Truvic Canister (e.g., an aspiration source)) via a path through the handle, a tubeset, and ultimately to the Truvic Canister, as shown in the annotated teardown image below. The second port provides a second fluid path from the chamber, back through the handle, the tubeset, and ultimately to the aspiration source.



(Annotated image of internal portion of controller handle housing)

327. The Symphony IFU for the Symphony system confirms that the Truvic Generator and Truvic Canister are configured to be fluidly connected to the second port of the clot collection reservoir.





Figure 6: Use of TRUVIC Tubeset from telescoping 16F Symphony Catheter and 24F Symphony Catheter to TRUVIC Generator and Canister


(Ex. B at 8.) And as shown in the Symphony overview video, the second port provides a second fluid path from the chamber for blood to be removed.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 2:03 (<https://www.truvic.com/symphony-product>).)

1 328. The Symphony IFU further confirms that the second port provides a second fluid
2 path that allows blood to evacuate from the chamber. Ex. B at 5.

3 329. The Symphony system practices the limitations of claim 1, including “a filter
4 removably positioned within the chamber, wherein the filter has a substantially cylindrical shape
5 extending from a first filter end portion to a second filter end portion, and wherein the filter body
6 extends continuously about the first filter end portion such that the filter encloses an interior
7 region around the second port,” as can be seen in Exhibit X. Specifically, the Symphony 24F
8 and 16F controller handles include a clot collection reservoir that has a filter positioned within
9 the chamber of the housing, where the filter body is substantially cylindrical in shape and
10 removable, as shown in the annotated images of the Symphony overview animation video below.



(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:21 (<https://www.truvic.com/symphony-product>).)




(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:47 (<https://www.truvic.com/symphony-product>).)

330. The Symphony overview animation video (as can be seen in the annotated images below) confirms that the substantially cylindrical shape of the Symphony's filter extends from a first filter end portion to a second filter end portion, such that the substantially cylindrical filter body extends about the first filter end portion.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 1:21 (<https://www.truvic.com/symphony-product>).)

331. The Symphony IFU confirms that the filter encloses an interior region around the second port, where it teaches that blood can be evacuated through the second port, but the clot material remains due to the filter inhibiting the clot to pass through the second port. Ex. B at 5 (“Confirm clot removal by briefly pressing the Vent Button to evacuate blood and visualize the clot in the container of the Handle.”). This is also shown in the image from Whipsaw and Symphony Thrombectomy System Overview Animation Video below:




(Annotated image of handle including clot container from Whipsaw at <https://www.whipsaw.com/work/imperative-care-symphony-thrombectomy-system>.)




(Annotated Symphony Thrombectomy System – Overview Animation Video at 2:03 (<https://www.truvic.com/symphony-product>).)

332. The Symphony system practices the limitations of claim 1, including “wherein the aspiration source is configured to generate negative pressure in the chamber via the second port to (a) draw blood and clot material from the aspiration catheter through the first port into the chamber and (b) draw blood through the filter into the interior region and through the interior region and through the second port,” as can be seen in Exhibit X. Specifically, the Symphony IFU confirms that the Truvic Generator and Truvic Canister (*e.g.*, aspiration source) is configured to generate a negative pressure to begin aspiration of clot material and blood via the first port. Ex. B at 5 (“Ensure the Generator is on and the Generator gauge reads -20 inHg or greater vacuum (refer to TRUVIC Generator IFU). Confirm tip of the Symphony Catheter is in the desired location. To begin aspiration, move the vacuum lever on the Handle to the “ON” position. When unrestricted blood flow through the clot container and into the canister is observed, move the lever on the Handle to the “OFF” position.”). The Symphony overview animation video further shows that clot material and blood are drawn through the first port into the chamber, as can be seen below.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 0:47 (<https://www.truvic.com/symphony-product>).)

333. The IFU also confirms that blood is drawn through the filter into the interior region of the filter and through the second port. Ex. B at 5. The Symphony overview animation video further shows that the blood is drawn through the interior of the filter and through the second port, which leaves the clot material remaining in the sealed chamber.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 2:03 (<https://www.truvic.com/symphony-product>).)

334. Truvic's Symphony Brochure confirms the flow of clot material and blood into the chamber and blood out of the chamber, capturing the clot in the clot container.




(Ex. A at 7.)

335. The Symphony system practices the limitations of claim 1, including “wherein the filter is configured to inhibit the clot material from passing through the filter into the interior region and through the second port,” as can be seen in Exhibit X. Specifically, the Symphony overview animation video shows that the filter inhibits clot material from passing through its interior region and through the second port. Instead, as can be seen below, the clot material remains in the chamber.




(Annotated Symphony Thrombectomy System – Overview Animation Video at 2:03
(<https://www.truvic.com/symphony-product>).)



(Annotated Symphony Thrombectomy System – Overview Animation Video at 2:05
(<https://www.truvic.com/symphony-product>).)

336. The Symphony IFU further confirms that the filter inhibits clot material from passing through its interior region and through the second port. Ex. B at 5.

337. The Symphony system practices the limitations of claim 1, including “wherein the housing is at least partially transparent to permit visualization of the clot material in the chamber outside the interior region,” as can be seen in Exhibit X. Specifically, the Symphony IFU confirms that a user of the Symphony system can visualize the clot material in the chamber due to the partial transparency of the outer plastic portion of the clot collection reservoir. Ex. B at 5. TruVic’s Symphony Brochure further confirms that the “TruView™ Clot Container” includes an at least partially transparent housing to permit visualization of the clot, as can be seen below.



(Ex. A at 6.)

338. Defendant directly infringes claims of the 12-'333 Patent, including claim 1, by making, using, selling, offering for sale, and/or importing Symphony system products, and when persons under Defendant’s direction and control make, sell, offer to sell, import and/or use (*e.g.*, to perform thrombectomy procedures using the hemostasis valves) Symphony system products.

339. Defendant induces infringement of claims of the 12-'333 Patent, including claim 1, by selling Symphony systems and teaching or directing others, including physicians, to use the Symphony products that practice claim 1. Defendant actively induces users of the system, *e.g.*, doctors, to perform thrombectomy procedures using the Symphony system.

340. Defendant teaches and/or directs others to perform thrombectomy on, for example,

1 deep vein thrombosis using the Symphony system (and components thereof) and to use
2 hemostasis valves of the system. Defendant, for example, provides Instructions for Use that state
3 that the “Symphony Thrombectomy System is intended for: The non-surgical removal of fresh,
4 soft emboli and thrombi from blood vessels.... The Symphony Thrombectomy System is
5 intended for use in the peripheral vasculature.” Ex. B at 2. The IFU further states that the
6 “Symphony Thrombectomy System is designed to remove thrombus/embolus (hereupon referred
7 to as ‘thrombus’ or ‘clot’) from the vascular using controlled aspiration.” *Id.* at 1. Defendant
8 further provides brochures and other materials, including animations videos, that detail how to
9 use the TruVic Symphony system. *See, e.g.,* <https://www.truvic.com/symphony-product>. Upon
10 information and belief, Defendant’s sales representatives additionally attend procedures and
11 instruct physicians regarding method of using the TruVic Symphony system including on
12 information and belief, methods of treating thrombi and emboli.

13 341. Defendant further engages in contributory infringement by offering to sell, selling,
14 and/or importing into the United States the Symphony system, knowing that these are
15 apparatuses for use in a patented process and constitute a material part of the invention that is
16 especially made or adapted for infringement of the claims of the 12-’333 Patent and not a staple
17 article or commodity of commerce suitable for substantial non-infringing uses.

18 342. Defendant’s infringement is with knowledge of the 12-’333 Patent and its claims.
19 Specifically, as described above, Inari notified Defendant, by e-mail dated February 14, 2025,
20 that its products would infringe claims of the 12-’333 Patent, when issued. Inari further notified
21 Defendant that it intended to seek leave to add the 12-’333 Patent to the Complaint and would
22 serve supplemental contentions for the 12-’333 Patent.

23 343. At a minimum, Defendant has notice of the 12-’333 Patent through the filing of
24 this Complaint. On information and belief, Defendant has had knowledge of the application that
25 would issue as the 12-’333 Patent via monitoring and investigation of Inari’s patent portfolio,
26 including in response to the notice letters provided by Inari regarding many other patents,
27 including family members of the 12-’333 Patent.

28 344. Defendant has continued its infringing activities, despite knowledge of the 12-’333

Patent, and such infringement has been and continues to be egregious and willful.

345. Defendant's infringement has caused and will continue to cause Inari substantial and irreparable harm, entitling Inari to an award of damages and injunctive relief.

PRAYER FOR RELIEF

WHEREFORE, Inari requests the following relief:

- A. A judgment that the Defendant has infringed one or more claims of each of the '910, 11-'333, '005, '691, '921, '012, '291, '580, '384,'669, and 12-'333 Patents and that such infringement is willful;
- B. A preliminary and permanent injunction enjoining Defendant and Defendant's officers, agents, servants, employees, attorneys and any other persons who are in active concert or participation with such persons, from making, selling, using, offering for sale or importing the Symphony Thrombectomy System and components thereof;
- C. For an award of damages, including lost profits, no less than a reasonable royalty under 35 U.S.C. § 284, arising from such infringement;
- D. For an award of reasonably royalties pursuant to 35 U.S.C. § 154(d) for provisional rights between the publication of a patent application and issuance of substantially identical claims;
- E. For increased damages pursuant to 35 U.S.C. § 285 or as otherwise permitted by law;
- F. For an award of attorneys' fees and costs pursuant to 35 U.S.C. § 285 or as otherwise permitted by law; and
- G. For such other relief as the Court deems just and proper.

1 Dated: March 5, 2025

PERKINS COIE LLP

2
3 By: /s/ Daniel T. Keese

4 Ramsey M. Al-Salam, Bar No. 109506
5 RAlsalam@perkinscoie.com
6 R. Tyler Kendrick (*pro hac vice*)
7 RKendrick@perkinscoie.com
8 PERKINS COIE LLP
1201 Third Avenue, Suite 4900
Seattle, Washington 98101-3099
Telephone: 206.359.8000
Facsimile: 206.359.9000

9 Amanda Tessar (*pro hac vice*)
10 ATessar@perkinscoie.com
11 Trevor Bervik (*pro hac vice*)
12 TBervik@perkinscoie.com
13 PERKINS COIE LLP
1900 Sixteenth Street, Suite 1400
Denver, Colorado 80202-5255
Telephone: 303.291.2300
Facsimile: 303.291.2400

14 Daniel T. Keese, Bar No. 280683
15 DKeese@perkinscoie.com
16 PERKINS COIE LLP
1120 NW Couch Street, 10th Floor
17 Portland, Oregon 97209-4128
Telephone: 503.757.2000
Facsimile: 503.727.2222

18
19 **ATTORNEYS FOR PLAINTIFF**
20 **INARI MEDICAL, INC.**
21
22
23
24
25
26
27
28